BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:295-302. [PMID: 23177515 DOI: 10.1016/s0140-6736(12)61857-1] [Cited by in Crossref: 774] [Cited by in F6Publishing: 379] [Article Influence: 77.4] [Reference Citation Analysis]
Number Citing Articles
1 Santangelo A, Rossato M, Lombardi G, Benfatto S, Lavezzari D, De Salvo GL, Indraccolo S, Dechecchi MC, Prandini P, Gambari R, Scapoli C, Di Gennaro G, Caccese M, Eoli M, Rudà R, Brandes AA, Ibrahim T, Rizzato S, Lolli I, Lippi G, Delledonne M, Zagonel V, Cabrini G. A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib. Neuro Oncol 2021;23:264-76. [PMID: 32661549 DOI: 10.1093/neuonc/noaa156] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
2 Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? Angiogenesis. 2017;20:185-204. [PMID: 28361267 DOI: 10.1007/s10456-017-9552-y] [Cited by in Crossref: 215] [Cited by in F6Publishing: 220] [Article Influence: 43.0] [Reference Citation Analysis]
3 Grothey A, George S, van Cutsem E, Blay JY, Sobrero A, Demetri GD. Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care. Oncologist 2014;19:669-80. [PMID: 24821824 DOI: 10.1634/theoncologist.2013-0059] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 5.9] [Reference Citation Analysis]
4 Zhang L, Cai J, Sun H, Shen L. Efficacy of compound traditional Chinese medicine oil in alleviating regorafenib-induced hand–foot skin reaction. Asia-Pacific Journal of Oncology Nursing 2021. [DOI: 10.1016/j.apjon.2021.10.002] [Reference Citation Analysis]
5 Angerilli V, Galuppini F, Businello G, Dal Santo L, Savarino E, Realdon S, Guzzardo V, Nicolè L, Lazzarin V, Lonardi S, Loupakis F, Fassan M. MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors. Biomedicines 2021;9:318. [PMID: 33801049 DOI: 10.3390/biomedicines9030318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Balachandran VP, Dematteo RP. Targeted therapy for cancer: the gastrointestinal stromal tumor model. Surg Oncol Clin N Am 2013;22:805-21. [PMID: 24012400 DOI: 10.1016/j.soc.2013.06.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sawaki A, Kanda T, Komatsu Y, Nishida T. Impact of rechallenge with imatinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib and sunitinib. Gastroenterol Res Pract 2014;2014:342986. [PMID: 24587795 DOI: 10.1155/2014/342986] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
8 Klug LR, Corless CL, Heinrich MC. Inhibition of KIT Tyrosine Kinase Activity: Two Decades After the First Approval. J Clin Oncol 2021;39:1674-86. [PMID: 33797935 DOI: 10.1200/JCO.20.03245] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Jakob J, Hohenberger P. Neoadjuvant Therapy to Downstage the Extent of Resection of Gastrointestinal Stromal Tumors. Visc Med. 2018;34:359-365. [PMID: 30498703 DOI: 10.1159/000493405] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 Yamamoto Y, Matsui J, Matsushima T, Obaishi H, Miyazaki K, Nakamura K, Tohyama O, Semba T, Yamaguchi A, Hoshi S, Mimura F, Haneda T, Fukuda Y, Kamata J, Takahashi K, Matsukura M, Wakabayashi T, Asada M, Nomoto K, Watanabe T, Dezso Z, Yoshimatsu K, Funahashi Y, Tsuruoka A. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell 2014;6:18. [DOI: 10.1186/2045-824x-6-18] [Cited by in Crossref: 174] [Cited by in F6Publishing: 99] [Article Influence: 21.8] [Reference Citation Analysis]
11 Suresh Babu MC, Chaudhuri T, Babu KG, Lakshmaiah KC, Lokanatha D, Jacob LA, Rudresha AH, Lokesh KN, Rajeev LK. Metastatic gastrointestinal stromal tumor: A regional cancer center experience of 44 cases. South Asian J Cancer 2017;6:118-21. [PMID: 28975120 DOI: 10.4103/sajc.sajc_290_16] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
12 Krishnamoorthy SK, Relias V, Sebastian S, Jayaraman V, Saif MW. Management of regorafenib-related toxicities: a review. Therap Adv Gastroenterol. 2015;8:285-297. [PMID: 26327919 DOI: 10.1177/1756283x15580743] [Cited by in Crossref: 44] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
13 Rutkowski P, Magnan H, Chou AJ, Benson C. Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series. BMC Cancer 2017;17:717. [PMID: 29110655 DOI: 10.1186/s12885-017-3727-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
14 Schuetze SM, Bolejack V, Thomas DG, von Mehren M, Patel S, Samuels B, Choy E, D'Amato G, Staddon AP, Ganjoo KN, Chow WA, Rushing DA, Forscher CA, Priebat DA, Loeb DM, Chugh R, Okuno S, Reinke DK, Baker LH. Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib. JAMA Oncol 2018;4:814-20. [PMID: 29710216 DOI: 10.1001/jamaoncol.2018.0601] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
15 Comunanza V, Bussolino F. Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies. Front Cell Dev Biol 2017;5:101. [PMID: 29270405 DOI: 10.3389/fcell.2017.00101] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
16 Gupta A, Ma S, Che K, Pobbati AV, Rubin BP. Inhibition of PI3K and MAPK pathways along with KIT inhibitors as a strategy to overcome drug resistance in gastrointestinal stromal tumors. PLoS One 2021;16:e0252689. [PMID: 34324512 DOI: 10.1371/journal.pone.0252689] [Reference Citation Analysis]
17 Bai H, Wang J, Phan CU, Chen Q, Hu X, Shao G, Zhou J, Lai L, Tang G. Cyclodextrin-based host-guest complexes loaded with regorafenib for colorectal cancer treatment. Nat Commun 2021;12:759. [PMID: 33536421 DOI: 10.1038/s41467-021-21071-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
18 Xu J, Xu RH, Qin S, Pan H, Bai Y, Chi Y, Wang L, Bi F, Cheng Y, Liu T, Ma D, Shen L, Ba Y, Liang J, Wang X, Yau TCC, Ma BB, Yeh KH, Lin JK, Kappeler C, Shapiro J, Kalmus J, Li J. Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial. J Gastroenterol Hepatol 2020;35:1307-16. [PMID: 31900959 DOI: 10.1111/jgh.14974] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. Gastric Cancer. 2016;19:3-14. [PMID: 26276366 DOI: 10.1007/s10120-015-0526-8] [Cited by in Crossref: 150] [Cited by in F6Publishing: 145] [Article Influence: 21.4] [Reference Citation Analysis]
20 Singeltary B, Ghose A, Sussman J, Choe K, Olowokure O. Durable response with a combination of imatinib and sorafenib in KIT exon 17 mutant gastrointestinal stromal tumor. J Gastrointest Oncol. 2014;5:E27-E29. [PMID: 24490049 DOI: 10.3978/j.issn.2078-6891.2013.058] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
21 Vergoulidou M. More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds. Biomark Insights 2015;10:33-40. [PMID: 26483606 DOI: 10.4137/BMI.S22436] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
22 Martin AJ, Gibbs E, Sjoquist K, Pavlakis N, Simes J, Price T, Shannon J, Gill S, Jain V, Liu G, Kannourakis G, Kim YH, Kim JW, Goldstein D; INTEGRATE I investigators. Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer 2018;21:473-80. [PMID: 28815316 DOI: 10.1007/s10120-017-0754-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
23 Joussen AM, Wolf S, Kaiser PK, Boyer D, Schmelter T, Sandbrink R, Zeitz O, Deeg G, Richter A, Zimmermann T, Hoechel J, Buetehorn U, Schmitt W, Stemper B, Boettger MK. The Developing Regorafenib Eye drops for neovascular Age-related Macular degeneration (DREAM) study: an open-label phase II trial. Br J Clin Pharmacol 2019;85:347-55. [PMID: 30341774 DOI: 10.1111/bcp.13794] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
24 Cohen NA, Kim TS, DeMatteo RP. Principles of Kinase Inhibitor Therapy for Solid Tumors. Ann Surg 2017;265:311-9. [PMID: 27058947 DOI: 10.1097/SLA.0000000000001740] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
25 Lostes-Bardaji MJ, García-Illescas D, Valverde C, Serrano C. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward. Ther Adv Med Oncol 2021;13:1758835920986498. [PMID: 33473249 DOI: 10.1177/1758835920986498] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Shima T, Taniguchi K, Tokumaru Y, Inomata Y, Arima J, Lee SW, Takabe K, Yoshida K, Uchiyama K. Glucose transporter‑1 inhibition overcomes imatinib resistance in gastrointestinal stromal tumor cells. Oncol Rep 2022;47:7. [PMID: 34738628 DOI: 10.3892/or.2021.8218] [Reference Citation Analysis]
27 Tian S, Nissenblatt M, Goyal S. Regorafenib-induced transverse myelopathy after stereotactic body radiation therapy. J Gastrointest Oncol 2014;5:E128-31. [PMID: 25436137 DOI: 10.3978/j.issn.2078-6891.2014.088] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Tsai HJ, Jiaang WT, Shih NY, Fletcher JA, Lin MJ, Yang MY, Chen CT, Hsu TJ, Wu CC, Lin HY, Chen LT. BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor. Cancer Sci 2018;109:3591-601. [PMID: 30142229 DOI: 10.1111/cas.13773] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
29 Rutkowski P, Andrzejuk J, Bylina E, Osuch C, Switaj T, Jerzak vel Dobosz A, Grzesiakowska U, Jurkowska M, Woźniak A, Limon J, Dębiec-Rychter M, Siedlecki JA. What are the current outcomes of advanced gastrointestinal stromal tumors: who are the long-term survivors treated initially with imatinib? Med Oncol 2013;30:765. [PMID: 24217870 DOI: 10.1007/s12032-013-0765-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
30 Huot JR, Essex AL, Gutierrez M, Barreto R, Wang M, Waning DL, Plotkin LI, Bonetto A. Chronic Treatment with Multi-Kinase Inhibitors Causes Differential Toxicities on Skeletal and Cardiac Muscles. Cancers (Basel) 2019;11:E571. [PMID: 31018508 DOI: 10.3390/cancers11040571] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
31 Kelly CM, Gutierrez Sainz L, Chi P. The management of metastatic GIST: current standard and investigational therapeutics. J Hematol Oncol. 2021;14:2. [PMID: 33402214 DOI: 10.1186/s13045-020-01026-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
32 Serrano C, Fletcher JA. Overcoming heterogenity in imatinib-resistant gastrointestinal stromal tumor. Oncotarget 2019;10:6286-7. [PMID: 31695836 DOI: 10.18632/oncotarget.27277] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
33 Liao W, Xu H, Hutton D, Wu Q, Zhou K, Luo H, Lei W, Feng M, Yang Y, Wen F, Li Q. Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors. Front Oncol 2021;11:692005. [PMID: 34938653 DOI: 10.3389/fonc.2021.692005] [Reference Citation Analysis]
34 Assi T, Watson S, Samra B, Rassy E, Le Cesne A, Italiano A, Mir O. Targeting the VEGF Pathway in Osteosarcoma. Cells 2021;10:1240. [PMID: 34069999 DOI: 10.3390/cells10051240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Inagaki Y, Kubota E, Mori Y, Aoyama M, Kataoka H, Johnston RN, Joh T. Anti-tumor efficacy of oncolytic reovirus against gastrointestinal stromal tumor cells. Oncotarget 2017;8:115632-46. [PMID: 29383187 DOI: 10.18632/oncotarget.23361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
36 Saponara M, Urbini M, Astolfi A, Indio V, Ercolani G, Del Gaudio M, Santini D, Pirini MG, Fiorentino M, Nannini M, Lolli C, Mandrioli A, Gatto L, Brandi G, Biasco G, Pinna AD, Pantaleo MA. Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS). Oncotarget 2015;6:42243-57. [PMID: 26544626 DOI: 10.18632/oncotarget.6278] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
37 Weekes C, Lockhart AC, Lee JJ, Sturm I, Cleton A, Huang F, Lenz HJ. A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors. Int J Cancer 2019;145:2450-8. [PMID: 30958892 DOI: 10.1002/ijc.32317] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
38 Farid M, Ong J, Chia C, Tan G, Teo M, Quek R, Teh J, Matchar D. Treatment of gastrointestinal tumor (GIST) of the rectum requiring abdominoperineal resection following neoadjuvant imatinib: a cost-effectiveness analysis. Clin Sarcoma Res 2020;10:13. [PMID: 32782781 DOI: 10.1186/s13569-020-00135-7] [Reference Citation Analysis]
39 Keunecke A, Hoefman S, Drenth HJ, Zisowsky J, Cleton A, Ploeger BA. Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake. Br J Clin Pharmacol 2020;86:2362-76. [PMID: 32358822 DOI: 10.1111/bcp.14334] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
40 Li X, He G, Su F, Chu Z, Xu L, Zhang Y, Zhou J, Ding Y. Regorafenib-loaded poly (lactide-co-glycolide) microspheres designed to improve transarterial chemoembolization therapy for hepatocellular carcinoma. Asian J Pharm Sci 2020;15:739-51. [PMID: 33363629 DOI: 10.1016/j.ajps.2020.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
41 Le Cesne A, Blay JY, Reichardt P, Joensuu H. Optimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppression. Oncologist. 2013;18:1192-1199. [PMID: 24136010 DOI: 10.1634/theoncologist.2012-0361] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
42 Drenner K, Basu GD, Goodman LJ, Ozols AA, LoBello JR, Royce T, Gordon MS, Borazanci EH, Steinbach MA, Trent J, Sharma S. The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series. Oncotarget 2021;12:1836-47. [PMID: 34504655 DOI: 10.18632/oncotarget.28046] [Reference Citation Analysis]
43 Liu P, Tan F, Liu H, Li B, Lei T, Zhao X. The Use of Molecular Subtypes for Precision Therapy of Recurrent and Metastatic Gastrointestinal Stromal Tumor. Onco Targets Ther 2020;13:2433-47. [PMID: 32273716 DOI: 10.2147/OTT.S241331] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
44 Bauer S, Hilger RA, Mühlenberg T, Grabellus F, Nagarajah J, Hoiczyk M, Reichardt A, Ahrens M, Reichardt P, Grunewald S, Scheulen ME, Pustowka A, Bock E, Schuler M, Pink D. Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors. Br J Cancer 2014;110:1155-62. [PMID: 24434430 DOI: 10.1038/bjc.2013.826] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
45 Wang T, Zhao H, Gao H, Zhu C, Xu Y, Bai L, Liu J, Yan F. Expression and phosphorylation of FOXO1 influences cell proliferation and apoptosis in the gastrointestinal stromal tumor cell line GIST-T1. Exp Ther Med. 2018;15:3197-3202. [PMID: 29545835 DOI: 10.3892/etm.2018.5853] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
46 Huang M, Yang W, Zhu J, Mariño-Enríquez A, Zhu C, Chen J, Wu Y, Quan Y, Qiu H, Li X, Chai L, Fletcher JA, Ou WB. Coordinated targeting of CK2 and KIT in gastrointestinal stromal tumours. Br J Cancer 2020;122:372-81. [PMID: 31776458 DOI: 10.1038/s41416-019-0657-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Woo J, Cohen SA, Grim JE. Targeted therapy in gastroesophageal cancers: past, present and future. Gastroenterol Rep (Oxf). 2015;3:316-329. [PMID: 26510453 DOI: 10.1093/gastro/gov052] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
48 Li K, Li J. Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application. Gastroenterol Res Pract. 2016;2016:4105615. [PMID: 26880889 DOI: 10.1155/2016/4105615] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
49 Ferraro D, Zalcberg J. Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy. Ther Adv Med Oncol. 2014;6:222-228. [PMID: 25342989 DOI: 10.1177/1758834014544892] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
50 Takeda K, Tsurumaru Y, Yamamoto Y, Araki K, Kogure Y, Mori K, Nakagawa K, Shimizu T, Matsuda G, Niino H, Sekido H, Kobayashi S, Morimoto M, Kunisaki C, Endo I. Treatment of hepatocellular carcinoma with hepatic vein tumor thrombosis protruding into the inferior vena cava by conversion surgery following chemotherapy with regorafenib: a case report. Clin J Gastroenterol 2020;13:428-33. [PMID: 31970661 DOI: 10.1007/s12328-019-01077-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
51 Boonstra PA, Gietema JA, Suurmeijer AJH, Groves MR, de Assis Batista F, Schuuring E, Reyners AKL. Tyrosine kinase inhibitor sensitive PDGFRΑ mutations in GIST: Two cases and review of the literature. Oncotarget 2017;8:109836-47. [PMID: 29312652 DOI: 10.18632/oncotarget.22663] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
52 Willobee BA, Quiroz HJ, Sussman MS, Thorson CM, Sola JE, Perez EA. Current treatment strategies in pediatric gastrointestinal stromal cell tumor. Transl Gastroenterol Hepatol 2018;3:53. [PMID: 30225387 DOI: 10.21037/tgh.2018.07.09] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
53 Song X, Shen L, Tong J, Kuang C, Zeng S, Schoen RE, Yu J, Pei H, Zhang L. Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer. Theranostics 2020;10:8098-110. [PMID: 32724460 DOI: 10.7150/thno.45363] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
54 Cuaron JJ, Goodman KA, Lee N, Wu AJ. External beam radiation therapy for locally advanced and metastatic gastrointestinal stromal tumors. Radiat Oncol. 2013;8:274. [PMID: 24267287 DOI: 10.1186/1748-717x-8-274] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
55 Boikos SA, Stratakis CA. The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations. Endocrine 2014;47:401-8. [PMID: 25027296 DOI: 10.1007/s12020-014-0346-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
56 Yin X, Yin Y, Shen C, Chen H, Wang J, Cai Z, Chen Z, Zhang B. Adverse events risk associated with regorafenib in the treatment of advanced solid tumors: meta-analysis of randomized controlled trials. Onco Targets Ther 2018;11:6405-14. [PMID: 30323618 DOI: 10.2147/OTT.S156760] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
57 Kotani K, Enomoto M, Okada M, Yoshida K, Motoyama H, Fujii H, Hagihara A, Uchida-Kobayashi S, Morikawa H, Murakami Y, Tamori A, Kawada N. Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma. Clin J Gastroenterol 2019;12:355-60. [PMID: 31020569 DOI: 10.1007/s12328-019-00983-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
58 Sharma A, Burridge PW, McKeithan WL, Serrano R, Shukla P, Sayed N, Churko JM, Kitani T, Wu H, Holmström A, Matsa E, Zhang Y, Kumar A, Fan AC, Del Álamo JC, Wu SM, Moslehi JJ, Mercola M, Wu JC. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. Sci Transl Med 2017;9:eaaf2584. [PMID: 28202772 DOI: 10.1126/scitranslmed.aaf2584] [Cited by in Crossref: 185] [Cited by in F6Publishing: 174] [Article Influence: 37.0] [Reference Citation Analysis]
59 Asija AP, Mejia AV, Prestipino A, Pillai MV. Gastrointestinal Stromal Tumors: A Review. Am J Ther 2016;23:e550-7. [PMID: 23942136 DOI: 10.1097/MJT.0b013e3182a1be76] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
60 Mühlenberg T, Grunewald S, Treckmann J, Podleska L, Schuler M, Fletcher JA, Bauer S. Inhibition of KIT-glycosylation by 2-deoxyglucose abrogates KIT-signaling and combination with ABT-263 synergistically induces apoptosis in gastrointestinal stromal tumor. PLoS One 2015;10:e0120531. [PMID: 25781619 DOI: 10.1371/journal.pone.0120531] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
61 Tsimberidou AM. Targeted therapy in cancer. Cancer Chemother Pharmacol 2015;76:1113-32. [PMID: 26391154 DOI: 10.1007/s00280-015-2861-1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 63] [Article Influence: 9.0] [Reference Citation Analysis]
62 Fernandez-Serra A, Moura DS, Sanchez-Izquierdo MD, Calabuig-Fariñas S, Lopez-Alvarez M, Martínez-Martínez A, Carrasco-Garcia I, Ramírez-Calvo M, Blanco-Alcaina E, López-Reig R, Obrador-Hevia A, Alemany R, Gutierrez A, Hindi N, Poveda A, Lopez-Guerrero JA, Martin-Broto J. Prognostic Impact of let-7e MicroRNA and Its Target Genes in Localized High-Risk Intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study. Cancers (Basel) 2020;12:E2979. [PMID: 33066614 DOI: 10.3390/cancers12102979] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Béchade D, Desjardin M, Castain C, Bernard PH, Fonck M. Fatal Acute Liver Failure as a Consequence of Regorafenib Treatment in a Metastatic Colon Cancer. Case Rep Oncol 2017;10:790-4. [PMID: 28966584 DOI: 10.1159/000479732] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
64 Panbude SN, Ankathi SK, Ramaswamy AT, Saklani AP. Gastrointestinal Stromal Tumor (GIST) from esophagus to anorectum - diagnosis, response evaluation and surveillance on computed tomography (CT) scan. Indian J Radiol Imaging 2019;29:133-40. [PMID: 31367084 DOI: 10.4103/ijri.IJRI_354_18] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 von Mehren M, Heinrich MC, Shi H, Iannazzo S, Mankoski R, Dimitrijević S, Hoehn G, Chiroli S, George S. Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data. BMC Cancer 2021;21:291. [PMID: 33740926 DOI: 10.1186/s12885-021-08013-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
66 Kim JJ, Ryu MH, Yoo C, Beck MY, Ma JE, Kang YK. Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib. Oncologist. 2019;24:e1212-e1218. [PMID: 31036770 DOI: 10.1634/theoncologist.2019-0033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
67 Oppelt PJ, Hirbe AC, Van Tine BA. Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review. J Gastrointest Oncol. 2017;8:466-473. [PMID: 28736634 DOI: 10.21037/jgo.2016.09.15] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
68 Schmidt T, Ghadimi M, Fuchs HF, Bruns CJ. [Surgical and interdisciplinary treatment of gastrointestinal stromal tumors]. Chirurg 2021. [PMID: 34709443 DOI: 10.1007/s00104-021-01527-1] [Reference Citation Analysis]
69 Zopf D, Fichtner I, Bhargava A, Steinke W, Thierauch KH, Diefenbach K, Wilhelm S, Hafner FT, Gerisch M. Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models. Cancer Med 2016;5:3176-85. [PMID: 27734608 DOI: 10.1002/cam4.883] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 5.8] [Reference Citation Analysis]
70 Kolsteren EEM, Deuning-Smit E, Prins JB, van der Graaf WTA, van Herpen CML, Lebel S, Thewes B, Kwakkenbos L, Custers JAE. Psychological aspects in patients with advanced cancer receiving lifelong systemic treatment: protocol for a scoping review. BMJ Open 2021;11:e042404. [PMID: 33518521 DOI: 10.1136/bmjopen-2020-042404] [Reference Citation Analysis]
71 Verma S, Reddy R, Chandrashekhara SH, Shamim SA, Tripathy S, Rastogi S. Avapritinib in advanced gastrointestinal stromal tumor: case series and review of the literature from a tertiary care center in India. Future Sci OA 2021;7:FSO676. [PMID: 33815822 DOI: 10.2144/fsoa-2020-0178] [Reference Citation Analysis]
72 Güller U, Tarantino I, Cerny T, Schmied BM, Warschkow R. Population-based SEER trend analysis of overall and cancer-specific survival in 5138 patients with gastrointestinal stromal tumor. BMC Cancer 2015;15:557. [PMID: 26223313 DOI: 10.1186/s12885-015-1554-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
73 Hemming ML, Lawlor MA, Andersen JL, Hagan T, Chipashvili O, Scott TG, Raut CP, Sicinska E, Armstrong SA, Demetri GD, Bradner JE. Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition. Cancer Res 2019;79:994-1009. [PMID: 30630822 DOI: 10.1158/0008-5472.CAN-18-1888] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
74 Yu K, Liu X, Jiang Z, Hu C, Zou F, Chen C, Ge J, Wu J, Liu X, Wang A, Wang W, Wang W, Qi Z, Wang B, Wang L, Yan H, Wang J, Ren T, Tang J, Liu Q, Liu J. Discovery of a highly selective KIT kinase primary V559D mutant inhibitor for gastrointestinal stromal tumors (GISTs). Oncotarget 2017;8:111110-8. [PMID: 29340041 DOI: 10.18632/oncotarget.22624] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
75 Brčić I, Argyropoulos A, Liegl-Atzwanger B. Update on Molecular Genetics of Gastrointestinal Stromal Tumors. Diagnostics (Basel) 2021;11:194. [PMID: 33525726 DOI: 10.3390/diagnostics11020194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Rimkus TK, Carpenter RL, Qasem S, Chan M, Lo HW. Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors. Cancers (Basel) 2016;8:E22. [PMID: 26891329 DOI: 10.3390/cancers8020022] [Cited by in Crossref: 314] [Cited by in F6Publishing: 296] [Article Influence: 52.3] [Reference Citation Analysis]
77 van der Graaf WTA, Tielen R, Bonenkamp JJ, Lemmens V, Verhoeven RHA, de Wilt JHW. Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era. Br J Surg 2018;105:1020-7. [PMID: 29664995 DOI: 10.1002/bjs.10809] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
78 Bose S, Ramaswamy A, Sahu A, Shetty O, Zanwar SS, Mirani J, Nashikkar C, Ostwal V. Clinical practice and outcomes in advanced gastrointestinal stromal tumor: Experience from an Indian tertiary care center. South Asian J Cancer 2017;6:110-2. [PMID: 28975117 DOI: 10.4103/sajc.sajc_323_16] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
79 Yun S, Kim WK, Kwon Y, Jang M, Bauer S, Kim H. Survivin is a novel transcription regulator of KIT and is downregulated by miRNA-494 in gastrointestinal stromal tumors. Int J Cancer 2018;142:2080-93. [PMID: 29277888 DOI: 10.1002/ijc.31235] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
80 Rosenbaum E, Kelly C, D'Angelo SP, Dickson MA, Gounder M, Keohan ML, Movva S, Condy M, Adamson T, Mcfadyen CR, Antonescu CR, Hwang S, Singer S, Qin LX, Tap WD, Chi P. A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor. Oncologist 2019;24:1309-e983. [PMID: 31213500 DOI: 10.1634/theoncologist.2019-0418] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
81 Wagner AJ, Kindler H, Gelderblom H, Schöffski P, Bauer S, Hohenberger P, Kopp HG, Lopez-Martin JA, Peeters M, Reichardt P, Qin A, Nippgen J, Ilaria RL, Rutkowski P. A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors. Ann Oncol 2017;28:541-6. [PMID: 28426120 DOI: 10.1093/annonc/mdw659] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
82 Invally M, Kanukula R, Salam MA, Shruthi G. Regorafenib-Associated Fatigue: A Systematic Review and Meta-analysis. American Journal of Therapeutics 2018;25:e715-7. [DOI: 10.1097/mjt.0000000000000731] [Reference Citation Analysis]
83 Hamacher R, Falkenhorst J, Treckmann J, Bauer S. [Imatinib and beyond-what is important for surgery?]. Chirurg 2019;90:462-9. [PMID: 30903227 DOI: 10.1007/s00104-019-0934-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
84 Nannini M, Valerio DS, Gruppioni E, Altimari A, Chiusole B, Saponara M, Pantaleo MA, Brunello A. Complete radiological response to first-line regorafenib in a patient with abdominal relapse of BRAF V600E mutated GIST. Therap Adv Gastroenterol 2020;13:1756284820927305. [PMID: 32647535 DOI: 10.1177/1756284820927305] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
85 Sato S, Tsujinaka T, Masuzawa T, Yamamoto K, Takahashi T, Yamashita Y, Fujita J, Takagi M, Hirota S, Nishida T. Role of metastasectomy for recurrent/metastatic gastrointestinal stromal tumors based on an analysis of the Kinki GIST registry. Surg Today 2017;47:58-64. [PMID: 27194124 DOI: 10.1007/s00595-016-1351-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
86 Blay JY, Hindi N, Bollard J, Aguiar S Jr, Angel M, Araya B, Badilla R, Bernabeu D, Campos F, Caro-Sánchez CHS, Carvajal B, Carvajal Montoya A, Casavilca-Zambrano S, Castro-Oliden V, Chacón M, Clara M, Collini P, Correa Genoroso R, Costa FD, Cuellar M, Dei Tos AP, Dominguez Malagon HR, Donati D, Dufresne A, Eriksson M, Farias-Loza M, Fernandez P, Frezza AM, Frisoni T, Garcia-Ortega DY, Gelderblom H, Gouin F, Gómez-Mateo MC, Gronchi A, Haro J, Huanca L, Jimenez N, Karanian M, Kasper B, Lopes David BB, Lopez-Pousa A, Lutter G, Martinez-Said H, Martinez-Tlahuel J, Mello CA, Morales Pérez JM, Moura David S, Nascimento AG, Ortiz-Cruz EJ, Palmerini E, Patel S, Pfluger Y, Provenzano S, Righi A, Rodriguez A, Salas R, Santos TTG, Scotlandi K, Soule T, Stacchiotti S, Valverde C, Waisberg F, Zamora Estrada E, Martin-Broto J. SELNET clinical practice guidelines for soft tissue sarcoma and GIST. Cancer Treat Rev 2022;102:102312. [PMID: 34798363 DOI: 10.1016/j.ctrv.2021.102312] [Reference Citation Analysis]
87 Steppan DA, Pratilas CA, Loeb DM. Targeted therapy for soft tissue sarcomas in adolescents and young adults. Adolesc Health Med Ther 2017;8:41-55. [PMID: 28408855 DOI: 10.2147/AHMT.S70377] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
88 Parab TM, DeRogatis MJ, Boaz AM, Grasso SA, Issack PS, Duarte DA, Urayeneza O, Vahdat S, Qiao JH, Hinika GS. Gastrointestinal stromal tumors: a comprehensive review. J Gastrointest Oncol. 2019;10:144-154. [PMID: 30788170 DOI: 10.21037/jgo.2018.08.20] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 10.8] [Reference Citation Analysis]
89 Sun W, Patel A, Normolle D, Patel K, Ohr J, Lee JJ, Bahary N, Chu E, Streeter N, Drummond S. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma. Cancer 2019;125:902-9. [PMID: 30561756 DOI: 10.1002/cncr.31872] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 10.5] [Reference Citation Analysis]
90 Kannaiyan R, Mahadevan D. A comprehensive review of protein kinase inhibitors for cancer therapy. Expert Rev Anticancer Ther 2018;18:1249-70. [PMID: 30259761 DOI: 10.1080/14737140.2018.1527688] [Cited by in Crossref: 57] [Cited by in F6Publishing: 44] [Article Influence: 14.3] [Reference Citation Analysis]
91 Balachandran VP, DeMatteo RP. Gastrointestinal stromal tumors: who should get imatinib and for how long? Adv Surg. 2014;48:165-183. [PMID: 25293614 DOI: 10.1016/j.yasu.2014.05.014] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
92 de Wit D, van Erp NP, Khosravan R, Wiltshire R, Allred R, Demetri GD, Guchelaar HJ, Gelderblom H. Effect of gastrointestinal resection on sunitinib exposure in patients with GIST. BMC Cancer 2014;14:575. [PMID: 25102852 DOI: 10.1186/1471-2407-14-575] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
93 Nakano K, Takahashi S. Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas. Int J Mol Sci. 2018;19. [PMID: 29510588 DOI: 10.3390/ijms19030739] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
94 Wang Y, Wozniak A, Wellens J, Gebreyohannes YK, Guillén MJ, Avilés PM, Debiec-Rychter M, Sciot R, Schöffski P. Plocabulin, a novel tubulin inhibitor, has potent antitumor activity in patient-derived xenograft models of gastrointestinal stromal tumors. Transl Oncol 2020;13:100832. [PMID: 32711367 DOI: 10.1016/j.tranon.2020.100832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
95 Chen Z, Wei J, Ma X, Yu J. Efficacy of EGFR-TKIs with or without angiogenesis inhibitors in advanced non-small-cell lung cancer: A systematic review and meta-analysis. J Cancer 2020;11:686-95. [PMID: 31942192 DOI: 10.7150/jca.34957] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
96 Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci 2020;77:1745-70. [PMID: 31690961 DOI: 10.1007/s00018-019-03351-7] [Cited by in Crossref: 157] [Cited by in F6Publishing: 151] [Article Influence: 52.3] [Reference Citation Analysis]
97 Corbin KS, Kindler HL, Liauw SL. Considering the role of radiation therapy for gastrointestinal stromal tumor. Onco Targets Ther. 2014;7:713-718. [PMID: 24872712 DOI: 10.2147/ott.s36873] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
98 Hsiao FC, Yeh CN, Chu PH. Regorafenib-Related Myocardial Injury during Atrial Fibrillation. Acta Cardiol Sin 2016;32:243-6. [PMID: 27122956 DOI: 10.6515/acs20150629b] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
99 Cohen NA, Zeng S, Seifert AM, Kim TS, Sorenson EC, Greer JB, Beckman MJ, Santamaria-Barria JA, Crawley MH, Green BL, Rossi F, Besmer P, Antonescu CR, DeMatteo RP. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors. Cancer Res 2015;75:2061-70. [PMID: 25836719 DOI: 10.1158/0008-5472.CAN-14-2564] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 4.9] [Reference Citation Analysis]
100 Zook P, Pathak HB, Belinsky MG, Gersz L, Devarajan K, Zhou Y, Godwin AK, von Mehren M, Rink L. Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor. Clin Cancer Res 2017;23:171-80. [PMID: 27370604 DOI: 10.1158/1078-0432.CCR-16-0529] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 4.2] [Reference Citation Analysis]
101 Garner AP, Gozgit JM, Anjum R, Vodala S, Schrock A, Zhou T, Serrano C, Eilers G, Zhu M, Ketzer J, Wardwell S, Ning Y, Song Y, Kohlmann A, Wang F, Clackson T, Heinrich MC, Fletcher JA, Bauer S, Rivera VM. Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. Clin Cancer Res. 2014;20:5745-5755. [PMID: 25239608 DOI: 10.1158/1078-0432.ccr-14-1397] [Cited by in Crossref: 95] [Cited by in F6Publishing: 55] [Article Influence: 11.9] [Reference Citation Analysis]
102 Wang YJ, Zhang YK, Zhang GN, Al Rihani SB, Wei MN, Gupta P, Zhang XY, Shukla S, Ambudkar SV, Kaddoumi A, Shi Z, Chen ZS. Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study. Cancer Lett 2017;396:145-54. [PMID: 28302530 DOI: 10.1016/j.canlet.2017.03.011] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 7.8] [Reference Citation Analysis]
103 Qiu HB, Zhou ZG, Feng XY, Liu XC, Guo J, Ma MZ, Chen YB, Sun XW, Zhou ZW. Advanced gastrointestinal stromal tumor patients benefit from palliative surgery after tyrosine kinase inhibitors therapy. Medicine (Baltimore) 2018;97:e9097. [PMID: 29480823 DOI: 10.1097/MD.0000000000009097] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
104 Ebinc S, Oruc Z. Treatment of gastrointestinal stromal tumors: A single-center experience. North Clin Istanb 2021;8:385-92. [PMID: 34585074 DOI: 10.14744/nci.2020.04468] [Reference Citation Analysis]
105 Janjigian YY, Vakiani E, Ku GY, Herrera JM, Tang LH, Bouvier N, Viale A, Socci ND, Capanu M, Berger M, Ilson DH. Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer. PLoS One 2015;10:e0134731. [PMID: 26275293 DOI: 10.1371/journal.pone.0134731] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
106 Ramaswamy A, Pande N, Shetty O, Shetty N, Gupta S, Ostwal V. Pazopanib in metastatic multiply treated progressive gastrointestinal stromal tumors: feasible and efficacious. J Gastrointest Oncol 2016;7:638-43. [PMID: 27563456 DOI: 10.21037/jgo.2016.03.06] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
107 Agulnik M, Attia S. Growing Role of Regorafenib in the Treatment of Patients with Sarcoma. Target Oncol 2018;13:417-22. [PMID: 29931504 DOI: 10.1007/s11523-018-0575-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
108 Zeiner PS, Kinzig M, Divé I, Maurer GD, Filipski K, Harter PN, Senft C, Bähr O, Hattingen E, Steinbach JP, Sörgel F, Voss M, Steidl E, Ronellenfitsch MW. Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients. J Clin Med 2019;8:E2031. [PMID: 31766326 DOI: 10.3390/jcm8122031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
109 Qin Z, Ma Y, Li F. Construction of a Pyrimidine Framework through [3 + 2 + 1] Annulation of Amidines, Ketones, and N,N-Dimethylaminoethanol as One Carbon Donor. J Org Chem 2021;86:13734-43. [PMID: 34541847 DOI: 10.1021/acs.joc.1c01847] [Reference Citation Analysis]
110 Wu X, Feng L, Liu Q, Xia D, Xu L. Partial response to imatinib treatment in a patient with unresectable gastrointestinal stromal tumor: A case report and mini literature review. Exp Ther Med 2016;12:2297-301. [PMID: 27698727 DOI: 10.3892/etm.2016.3614] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
111 Pitoia F. Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6-NTRK3 gene fusion. Clin Case Rep 2021;9:1905-12. [PMID: 33936613 DOI: 10.1002/ccr3.3900] [Reference Citation Analysis]
112 Van Looy T, Wozniak A, Floris G, Li H, Wellens J, Vanleeuw U, Sciot R, Debiec-Rychter M, Schöffski P. Therapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft Models. Transl Oncol 2015;8:112-8. [PMID: 25926077 DOI: 10.1016/j.tranon.2015.02.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
113 Kim JH, Ryu MH, Yoo C, Chae H, Na H, Beck M, Kim BS, Yoo MW, Yook JH, Kim BS, Kim KH, Kim CW, Kang YK. Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience. Cancer Med 2019;8:1034-43. [PMID: 30693663 DOI: 10.1002/cam4.1994] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
114 Kim TS, Cavnar MJ, Cohen NA, Sorenson EC, Greer JB, Seifert AM, Crawley MH, Green BL, Popow R, Pillarsetty N, Veach DR, Ku AT, Rossi F, Besmer P, Antonescu CR, Zeng S, Dematteo RP. Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor. Clin Cancer Res 2014;20:2350-62. [PMID: 24583793 DOI: 10.1158/1078-0432.CCR-13-3033] [Cited by in Crossref: 39] [Cited by in F6Publishing: 26] [Article Influence: 4.9] [Reference Citation Analysis]
115 Mayer B, Karakhanova S, Bauer N, Liu L, Zhu Y, Philippov PP, Werner J, Bazhin AV. A marginal anticancer effect of regorafenib on pancreatic carcinoma cells in vitro, ex vivo, and in vivo. Naunyn Schmiedebergs Arch Pharmacol 2017;390:1125-34. [PMID: 28779210 DOI: 10.1007/s00210-017-1412-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
116 Sunakawa Y, Furuse J, Okusaka T, Ikeda M, Nagashima F, Ueno H, Mitsunaga S, Hashizume K, Ito Y, Sasaki Y. Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics. Invest New Drugs 2014;32:104-12. [PMID: 23553067 DOI: 10.1007/s10637-013-9953-8] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
117 Van Looy T, Gebreyohannes YK, Wozniak A, Cornillie J, Wellens J, Li H, Vanleeuw U, Floris G, Debiec-Rychter M, Sciot R, Schöffski P. Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors. Clin Sarcoma Res 2014;4:10. [PMID: 25132955 DOI: 10.1186/2045-3329-4-10] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
118 Zhang S, Zhang L, Jiang Z, Guo Y, Zhao H, Sun J. Protein tyrosine phosphatase receptor type E (PTPRE) regulates the activation of wild-type KIT and KIT mutants differently. Biochem Biophys Rep 2021;26:100974. [PMID: 33732906 DOI: 10.1016/j.bbrep.2021.100974] [Reference Citation Analysis]
119 Liu W, Zeng X, Yin Y, Li C, Yang W, Wan W, Shi L, Wang G, Tao K, Zhang P. Targeting the WEE1 kinase strengthens the antitumor activity of imatinib via promoting KIT autophagic degradation in gastrointestinal stromal tumors. Gastric Cancer 2020;23:39-51. [PMID: 31197522 DOI: 10.1007/s10120-019-00977-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
120 Fendrich V, Bartsch DK. [Gastrointestinal stromal tumors: diagnostics and therapy]. Chirurg 2014;85:545-56. [PMID: 24858723 DOI: 10.1007/s00104-013-2681-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
121 Zhu N, Weng S, Wang J, Chen J, Yu L, Fang X, Yuan Y. Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors. J Cancer Res Clin Oncol 2019;145:3021-36. [PMID: 31617075 DOI: 10.1007/s00432-019-03044-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
122 Vandenberghe P, Hagué P, Hockman SC, Manganiello VC, Demetter P, Erneux C, Vanderwinden JM. Phosphodiesterase 3A: a new player in development of interstitial cells of Cajal and a prospective target in gastrointestinal stromal tumors (GIST). Oncotarget 2017;8:41026-43. [PMID: 28454120 DOI: 10.18632/oncotarget.17010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
123 Brodowicz T, Liegl-Atzwanger B, Penel N, Mir O, Blay JY, Kashofer K, Le Cesne A, Decoupigny E, Wallet J, Hamacher R, Deley ML. Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study. Cancers (Basel) 2020;12:E3746. [PMID: 33322802 DOI: 10.3390/cancers12123746] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
124 Her Z, Yong KSM, Paramasivam K, Tan WWS, Chan XY, Tan SY, Liu M, Fan Y, Linn YC, Hui KM, Surana U, Chen Q. An improved pre-clinical patient-derived liquid xenograft mouse model for acute myeloid leukemia. J Hematol Oncol 2017;10:162. [PMID: 28985760 DOI: 10.1186/s13045-017-0532-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
125 Nannini M, Rizzo A, Indio V, Schipani A, Astolfi A, Pantaleo MA. Targeted therapy in SDH-deficient GIST. Ther Adv Med Oncol 2021;13:17588359211023278. [PMID: 34262616 DOI: 10.1177/17588359211023278] [Reference Citation Analysis]
126 Ma Q, Gu LY, Ren YY, Zeng LL, Gong T, Zhong DS. Increased risk of severe infections in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis. Onco Targets Ther 2015;8:2361-74. [PMID: 26355897 DOI: 10.2147/OTT.S87298] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
127 Mahadevan D, Theiss N, Morales C, Stejskal AE, Cooke LS, Zhu M, Kurtzman D, Swart R, Ong E, Qi W. Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST). Oncotarget 2015;6:1954-66. [PMID: 25557174 DOI: 10.18632/oncotarget.3021] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
128 Alturkmani HJ, Pessetto ZY, Godwin AK. Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor. Expert Opin Investig Drugs 2015;24:1045-58. [PMID: 26098203 DOI: 10.1517/13543784.2015.1046594] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
129 Pang YY, Tan YL, Ho HK. Investigation of the effect of plasma albumin levels on regorafenib-induced hepatotoxicity using a validated liquid chromatography-tandem mass spectrometry method. Journal of Chromatography B 2017;1061-1062:220-4. [DOI: 10.1016/j.jchromb.2017.07.023] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
130 Nannini M, Nigro MC, Vincenzi B, Fumagalli E, Grignani G, D'Ambrosio L, Badalamenti G, Incorvaia L, Bracci R, Gasperoni S, Saponara M, Gatto L, Indio V, Astolfi A, Di Scioscio V, Casali PG, Tonini G, Aglietta M, Russo A, Biasco G, Pantaleo MA. Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice. Ther Adv Med Oncol 2017;9:731-9. [PMID: 29449894 DOI: 10.1177/1758834017742627] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
131 Kiesewetter B, Raderer M, Prager GW, Fuereder T, Marosi C, Preusser M, Krainer M, Locker GJ, Brodowicz T, Zielinski CC. The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna. ESMO Open 2017;2:e000166. [PMID: 28761758 DOI: 10.1136/esmoopen-2017-000166] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
132 Rare Tumors GI Group, Farhat F, Farsi AA, Mohieldin A, Bahrani BA, Sbaity E, Jaffar H, Kattan J, Rasul K, Saad K, Assi T, Morsi WE, Abood RA. Comprehensive review into the challenges of gastrointestinal tumors in the Gulf and Levant countries. World J Clin Cases 2020; 8(3): 487-503 [PMID: 32110658 DOI: 10.12998/wjcc.v8.i3.487] [Reference Citation Analysis]
133 Rizzo A, Nannini M, Novelli M, Dalia Ricci A, Scioscio VD, Pantaleo MA. Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis. Ther Adv Med Oncol 2020;12:1758835920936932. [PMID: 32684988 DOI: 10.1177/1758835920936932] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
134 Foster BM, Zaidi D, Young TR, Mobley ME, Kerr BA. CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance. Biomedicines 2018;6:E31. [PMID: 29518044 DOI: 10.3390/biomedicines6010031] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 9.8] [Reference Citation Analysis]
135 Qin J, Shaukat I, Mainard D, Netter P, Barré L, Ouzzine M. Constitutive activation of EGFR is associated with tumor progression and plays a prominent role in malignant phenotype of chondrosarcoma. Oncotarget 2019;10:3166-82. [PMID: 31139331 DOI: 10.18632/oncotarget.26899] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
136 Yeh CN, Chen MH, Chen YY, Yang CY, Yen CC, Tzen CY, Chen LT, Chen JS. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17. Oncotarget 2017;8:44121-30. [PMID: 28487491 DOI: 10.18632/oncotarget.17310] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
137 Songdej N, von Mehren M. GIST treatment options after tyrosine kinase inhibitors. Curr Treat Options Oncol. 2014;15:493-506. [PMID: 24952730 DOI: 10.1007/s11864-014-0295-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
138 Rammohan A, Sathyanesan J, Rajendran K, Pitchaimuthu A, Perumal SK, Srinivasan U, Ramasamy R, Palaniappan R, Govindan M. A gist of gastrointestinal stromal tumors: A review. World J Gastrointest Oncol 2013; 5(6): 102-112 [PMID: 23847717 DOI: 10.4251/wjgo.v5.i6.102] [Cited by in CrossRef: 77] [Cited by in F6Publishing: 77] [Article Influence: 8.6] [Reference Citation Analysis]
139 Fröbom R, Berglund E, Berglund D, Nilsson IL, Åhlén J, von Sivers K, Linder-Stragliotto C, Suenaert P, Karlsson-Parra A, Bränström R. Phase I trial evaluating safety and efficacy of intratumorally administered inflammatory allogeneic dendritic cells (ilixadencel) in advanced gastrointestinal stromal tumors. Cancer Immunol Immunother 2020;69:2393-401. [PMID: 32535637 DOI: 10.1007/s00262-020-02625-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
140 Lazăr DC, Tăban S, Cornianu M, Faur A, Goldiş A. New advances in targeted gastric cancer treatment. World J Gastroenterol 2016; 22(30): 6776-6799 [PMID: 27570417 DOI: 10.3748/wjg.v22.i30.6776] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 47] [Article Influence: 8.0] [Reference Citation Analysis]
141 Yeh CN, Hu CH, Wang SY, Wu CE, Chen JS, Tsai CY, Hsu JT, Yeh TS. Cytoreductive Surgery may be beneficial for highly selected patients with Metastatic Gastrointestinal Stromal Tumors receiving Regorafenib facing Local Progression: A Case Controlled Study. J Cancer 2021;12:3335-43. [PMID: 33976743 DOI: 10.7150/jca.50324] [Reference Citation Analysis]
142 Liu D, Ma X, Xiao D, Jia Y, Wang Y. Efficacy and safety of targeting VEGFR drugs in treatment for advanced or metastatic gastric cancer: a systemic review and meta-analysis. Oncotarget 2018;9:8120-32. [PMID: 29487720 DOI: 10.18632/oncotarget.23429] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
143 Zhang JQ, Zeng S, Vitiello GA, Seifert AM, Medina BD, Beckman MJ, Loo JK, Santamaria-Barria J, Maltbaek JH, Param NJ, Moral JA, Zhao JN, Balachandran V, Rossi F, Antonescu CR, DeMatteo RP. Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors. Cancer Immunol Res 2018;6:434-47. [PMID: 29467128 DOI: 10.1158/2326-6066.CIR-17-0345] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
144 Banerjee S, Kumar A, Lopez N, Zhao B, Tang CM, Yebra M, Yoon H, Murphy JD, Sicklick JK. Cost-effectiveness Analysis of Genetic Testing and Tailored First-Line Therapy for Patients With Metastatic Gastrointestinal Stromal Tumors. JAMA Netw Open 2020;3:e2013565. [PMID: 32986105 DOI: 10.1001/jamanetworkopen.2020.13565] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
145 Mariño-Enríquez A, Bovée JV. Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma. Surg Pathol Clin 2016;9:457-73. [PMID: 27523972 DOI: 10.1016/j.path.2016.04.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 5.6] [Reference Citation Analysis]
146 Pavlakis N, Sjoquist KM, Martin AJ, Tsobanis E, Yip S, Kang YK, Bang YJ, Alcindor T, O'Callaghan CJ, Burnell MJ, Tebbutt NC, Rha SY, Lee J, Cho JY, Lipton LR, Wong M, Strickland A, Kim JW, Zalcberg JR, Simes J, Goldstein D. Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial. J Clin Oncol. 2016;34:2728-2735. [PMID: 27325864 DOI: 10.1200/jco.2015.65.1901] [Cited by in Crossref: 110] [Cited by in F6Publishing: 67] [Article Influence: 18.3] [Reference Citation Analysis]
147 Zhao B, Zhao H. Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib. Oncotarget 2017;8:93813-24. [PMID: 29212191 DOI: 10.18632/oncotarget.21217] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
148 Poole CD, Connolly MP, Chang J, Currie CJ. Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo. Gastric Cancer. 2014;Epub ahead of print. [PMID: 24957256 DOI: 10.1007/s10120-014-0391-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
149 Kang YK, Ryu MH, Yoo C, Ryoo BY, Kim HJ, Lee JJ, Nam BH, Ramaiya N, Jagannathan J, Demetri GD. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2013;14:1175-82. [PMID: 24140183 DOI: 10.1016/S1470-2045(13)70453-4] [Cited by in Crossref: 111] [Cited by in F6Publishing: 48] [Article Influence: 12.3] [Reference Citation Analysis]
150 Montor WR, Salas AROSE, Melo FHM. Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors. Mol Cancer 2018;17:55. [PMID: 29455659 DOI: 10.1186/s12943-018-0792-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
151 Tong J, Tan S, Zou F, Yu J, Zhang L. FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation. Oncogene 2017;36:787-96. [PMID: 27399335 DOI: 10.1038/onc.2016.247] [Cited by in Crossref: 93] [Cited by in F6Publishing: 102] [Article Influence: 15.5] [Reference Citation Analysis]
152 Urban C, Anadkat MJ. A review of cutaneous toxicities from targeted therapies in the treatment of colorectal cancers. J Gastrointest Oncol 2013;4:319-27. [PMID: 23997943 DOI: 10.3978/j.issn.2078-6891.2013.033] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
153 Cao M, Li F, Wang Y, Zhang J. Treatment-related serious adverse events and fatal adverse events with regorafenib in cancer patients: a meta-analysis of phase 3 randomized controlled trials. Invest New Drugs 2017;35:834-8. [PMID: 28936569 DOI: 10.1007/s10637-017-0512-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
154 Tu Y, Zuo R, Ni N, Eilers G, Wu D, Pei Y, Nie Z, Wu Y, Wu Y, Ou WB. Activated tyrosine kinases in gastrointestinal stromal tumor with loss of KIT oncoprotein expression. Cell Cycle 2018;17:2577-92. [PMID: 30488756 DOI: 10.1080/15384101.2018.1553335] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
155 Brodowicz T, Liegl-Atzwager B, Tresch E, Taieb S, Kramar A, Gruenwald V, Vanseymortier M, Clisant S, Blay JY, Le Cesne A, Penel N. Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial. BMC Cancer 2015;15:127. [PMID: 25884155 DOI: 10.1186/s12885-015-1143-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
156 Riedel RF, Ballman KV, Lu Y, Attia S, Loggers ET, Ganjoo KN, Livingston MB, Chow W, Wright J, Ward JH, Rushing D, Okuno SH, Reed DR, Liebner DA, Keedy VL, Mascarenhas L, Davis LE, Ryan C, Reinke DK, Maki RG. A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study. Oncologist 2020;25:e1655-62. [PMID: 32701199 DOI: 10.1634/theoncologist.2020-0679] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
157 Kollàr A, Maruzzo M, Messiou C, Cartwright E, Miah A, Martin-Liberal J, Thway K, McGrath E, Dunlop A, Khabra K, Seddon B, Dileo P, Linch M, Judson I, Benson C. Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program. Clin Sarcoma Res 2014;4:17. [PMID: 25905001 DOI: 10.1186/2045-3329-4-17] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
158 Tang L, Sui Y, Zhong Z, Damen FC, Li J, Shen L, Sun Y, Zhou XJ. Non-Gaussian diffusion imaging with a fractional order calculus model to predict response of gastrointestinal stromal tumor to second-line sunitinib therapy. Magn Reson Med 2018;79:1399-406. [PMID: 28643387 DOI: 10.1002/mrm.26798] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
159 Tang L, Zhou XJ. Diffusion MRI of cancer: From low to high b-values. J Magn Reson Imaging 2019;49:23-40. [PMID: 30311988 DOI: 10.1002/jmri.26293] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 10.3] [Reference Citation Analysis]
160 Cai Z, Chen X, Zhang B, Cao D. Apatinib Treatment in Metastatic Gastrointestinal Stromal Tumor. Front Oncol 2019;9:470. [PMID: 31245289 DOI: 10.3389/fonc.2019.00470] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
161 de Man FM, Hussaarts KGAM, de With M, Oomen-de Hoop E, de Bruijn P, van Halteren HK, van der Burg-de Graauw NCHP, Eskens FALM, van Gelder T, van Leeuwen RWF, Mathijssen RHJ. Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study. Clin Pharmacol Ther 2019;105:1456-61. [PMID: 30570132 DOI: 10.1002/cpt.1331] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
162 Ganjoo KN, Villalobos VM, Kamaya A, Fisher GA, Butrynski JE, Morgan JA, Wagner AJ, D'Adamo D, McMillan A, Demetri GD, George S. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib. Ann Oncol 2014;25:236-40. [PMID: 24356634 DOI: 10.1093/annonc/mdt484] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
163 Blay JY, Serrano C, Heinrich MC, Zalcberg J, Bauer S, Gelderblom H, Schöffski P, Jones RL, Attia S, D'Amato G, Chi P, Reichardt P, Meade J, Shi K, Ruiz-Soto R, George S, von Mehren M. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2020;21:923-34. [PMID: 32511981 DOI: 10.1016/S1470-2045(20)30168-6] [Cited by in Crossref: 59] [Cited by in F6Publishing: 23] [Article Influence: 29.5] [Reference Citation Analysis]
164 Omerza CR, Bouman AK, Bulinski PP. A Rare Case of a Gastrointestinal Stromal Tumor (GIST) Presenting as a Perforated Meckel's Diverticulum. J Gastrointest Cancer 2017;48:76-9. [PMID: 26820464 DOI: 10.1007/s12029-016-9803-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
165 Li J, Wang M, Zhang B, Wu X, Lin TL, Liu XF, Zhou Y, Zhang XH, Xu H, Shen LJ, Zou J, Lu P, Zhang D, Gu WJ, Zhang MX, Pan J, Cao H, Chinese Society of Surgeons for Gastrointestinal Stromal Tumor of the Chinese Medical Doctor Association. Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors. World J Gastroenterol 2018; 24(46): 5189-5202 [PMID: 30581268 DOI: 10.3748/wjg.v24.i46.5189] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
166 Schvartsman G, Wagner MJ, Amini B, Zobniw CM, Trinh VA, Barbo AG, Lin HY, Wang WL, Conley AP, Ravi V, Araujo DM, Zarzour MA, Benjamin RS, Patel S, Somaiah N. Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients. Sci Rep 2017;7:9519. [PMID: 28842575 DOI: 10.1038/s41598-017-09132-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
167 Miyake K, Kawaguchi K, Miyake M, Zhao M, Kiyuna T, Igarashi K, Zhang Z, Murakami T, Li Y, Nelson SD, Bouvet M, Elliott I, Russell TA, Singh AS, Hiroshima Y, Momiyama M, Matsuyama R, Chishima T, Singh SR, Endo I, Eilber FC, Hoffman RM. Tumor-targeting Salmonella typhimurium A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations. Heliyon 2018;4:e00643. [PMID: 30003151 DOI: 10.1016/j.heliyon.2018.e00643] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
168 Wu CE, Tzen CY, Wang SY, Yeh CN. Clinical Diagnosis of Gastrointestinal Stromal Tumor (GIST): From the Molecular Genetic Point of View. Cancers (Basel). 2019;11:E679. [PMID: 31100836 DOI: 10.3390/cancers11050679] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
169 Kanda T, Ishikawa T, Kosugi SI, Ueki K, Naito T, Wakai T, Hirota S. Prognostic factors after imatinib secondary resistance: survival analysis in patients with unresectable and metastatic gastrointestinal stromal tumors. Int J Clin Oncol 2016;21:295-301. [PMID: 26386705 DOI: 10.1007/s10147-015-0903-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
170 Napolitano A, Vincenzi B. Secondary KIT mutations: the GIST of drug resistance and sensitivity. Br J Cancer 2019;120:577-8. [PMID: 30792534 DOI: 10.1038/s41416-019-0388-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
171 Jiang J, Zhang L, Chen H, Lei Y, Zhang T, Wang Y, Jin P, Lan J, Zhou L, Huang Z, Li B, Liu Y, Gao W, Xie K, Zhou L, Nice EC, Peng Y, Cao Y, Wei Y, Wang K, Huang C. Regorafenib induces lethal autophagy arrest by stabilizing PSAT1 in glioblastoma. Autophagy 2020;16:106-22. [PMID: 30909789 DOI: 10.1080/15548627.2019.1598752] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
172 Kozinova M, Joshi S, Ye S, Belinsky MG, Sharipova D, Farma JM, Reddy SS, Litwin S, Devarajan K, Campos AR, Yu Y, Schwartz B, von Mehren M, Rink L. Combined Inhibition of AKT and KIT Restores Expression of Programmed Cell Death 4 (PDCD4) in Gastrointestinal Stromal Tumor. Cancers (Basel) 2021;13:3699. [PMID: 34359600 DOI: 10.3390/cancers13153699] [Reference Citation Analysis]
173 Li J, Gu J. Risk of gastrointestinal events with newly approved (after 2011) vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2017;73:1209-17. [PMID: 28710508 DOI: 10.1007/s00228-017-2299-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
174 Liu Y, von Mehren M. Randomized Clinical Trials in Gastrointestinal Stromal Tumors. Surg Oncol Clin N Am 2017;26:545-57. [PMID: 28923219 DOI: 10.1016/j.soc.2017.05.004] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
175 Kim ST, Kim TW, Kim KP, Kim TY, Han SW, Lee JY, Lim SH, Lee MY, Kim H, Park YS. Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer. Cancer Res Treat 2015;47:790-5. [PMID: 25672574 DOI: 10.4143/crt.2014.126] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
176 Zhang J, Zhang Y, Tang S, Jiang L, He Q, Hamblin LT, He J, Xu Z, Wu J, Chen Y, Liang H, Chen D, Huang Y, Wang X, Deng K, Jiang S, Zhou J, Xu J, Chen X, Liang W, He J. Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour. BMJ Open 2018;8:e017240. [PMID: 30206071 DOI: 10.1136/bmjopen-2017-017240] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
177 Lombardi G, Caccese M, Padovan M, Cerretti G, Pintacuda G, Manara R, Di Sarra F, Zagonel V. Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study. Cancers (Basel) 2021;13:4731. [PMID: 34572958 DOI: 10.3390/cancers13184731] [Reference Citation Analysis]
178 Hofheinz RD, Bruix J, Demetri GD, Grothey A, Marian M, Bartsch J, Odom D. Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types. Cancer Manag Res 2021;13:5523-33. [PMID: 34285574 DOI: 10.2147/CMAR.S305939] [Reference Citation Analysis]
179 Ivanyi P, Eggers H, Hornig M, Kasper B, Heissner K, Kopp HG, Kirstein M, Ganser A, Grünwald V. Hepatic toxicity during regorafenib treatment in patients with metastatic gastrointestinal stromal tumors. Mol Clin Oncol 2020;13:72. [PMID: 33005406 DOI: 10.3892/mco.2020.2143] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
180 Jatoi A, Ou FS, Ahn DH, Zemla TJ, Le-Rademacher JG, Boland P, Ciombor KK, Jacobs NL, Pasche B, Cleary JM, McCune JS, Pedersen KS, Barzi A, Chiorean EG, Heying EN, Lenz HJ, Sloan JA, Grothey A, Lacouture ME, Bekaii-Saab T. Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. Oncologist 2021;26:610-8. [PMID: 33604969 DOI: 10.1002/onco.13730] [Reference Citation Analysis]
181 Mu ZM, Xie YC, Peng XX, Zhang H, Hui G, Wu H, Liu JX, Chen BK, Wu D, Ye YW. Long-term survival after enucleation of a giant esophageal gastrointestinal stromal tumor. World J Gastroenterol 2014; 20(37): 13632-13636 [PMID: 25309096 DOI: 10.3748/wjg.v20.i37.13632] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
182 Rahou FZ, Miry A, Bennani A, Bouziane M. Neurofibromatosis type 1 associated multiple and cystic gastrointestinal tumors: 02 case reports. Int J Surg Case Rep 2020;76:210-6. [PMID: 33049646 DOI: 10.1016/j.ijscr.2020.09.072] [Reference Citation Analysis]
183 Metaxas Y, Oikonomopoulos G, Pentheroudakis G. Update on clinical research and state of the art management of patients with advanced sarcomas and GIST. ESMO Open 2016;1:e000065. [PMID: 27843616 DOI: 10.1136/esmoopen-2016-000065] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
184 Van Weehaeghe D, Gheysens O, Vandecaveye V, Schöffski P, Van Laere K, Deroose CM. Mixed response on regorafenib treatment for GIST (gastro-intestinal stromal tumor) according to 18F-FDG-PET/CT. BMC Cancer 2018;18:253. [PMID: 29506493 DOI: 10.1186/s12885-018-4154-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
185 Ma X, Wu Y, Zhang T, Song H, Jv H, Guo W, Ren G. The clinical significance of c-Kit mutations in metastatic oral mucosal melanoma in China. Oncotarget 2017;8:82661-73. [PMID: 29137292 DOI: 10.18632/oncotarget.19746] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
186 D'Alessandro R, Refolo MG, Lippolis C, Messa C, Cavallini A, Rossi R, Resta L, Di Carlo A, Carr BI. Reversibility of regorafenib effects in hepatocellular carcinoma cells. Cancer Chemother Pharmacol 2013;72:869-77. [PMID: 23959464 DOI: 10.1007/s00280-013-2269-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
187 Helsten T, Schwaederle M, Kurzrock R. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. Cancer Metastasis Rev 2015;34:479-96. [PMID: 26224133 DOI: 10.1007/s10555-015-9579-8] [Cited by in Crossref: 66] [Cited by in F6Publishing: 65] [Article Influence: 11.0] [Reference Citation Analysis]
188 Marretta AL, Di Lorenzo G, Ribera D, Cannella L, von Arx C, Bracigliano A, Clemente O, Tafuto R, Pizzolorusso A, Tafuto S. Selinexor and the Selective Inhibition of Nuclear Export: A New Perspective on the Treatment of Sarcomas and Other Solid and Non-Solid Tumors. Pharmaceutics 2021;13:1522. [PMID: 34575598 DOI: 10.3390/pharmaceutics13091522] [Reference Citation Analysis]
189 Szucs Z, Jones RL. Perspectives on the evolving state of the art management of gastrointestinal stromal tumours. Transl Gastroenterol Hepatol 2018;3:21. [PMID: 29780899 DOI: 10.21037/tgh.2018.04.02] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
190 Facciorusso A, Abd El Aziz MA, Sacco R. Efficacy of Regorafenib in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis. Cancers (Basel). 2019;12. [PMID: 31877664 DOI: 10.3390/cancers12010036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
191 Brzozowska M, Wierzba W, Szafraniec-Buryło S, Czech M, Połowinczak-Przybyłek J, Potemski P, Śliwczyński A. Real-World Evidence of Patient Outcome Following Treatment of Advanced Gastrointestinal Stromal Tumor (GIST) with Imatinib, Sunitinib, and Sorafenib in Publicly Funded Health Care in Poland. Med Sci Monit 2019;25:3846-53. [PMID: 31121600 DOI: 10.12659/MSM.914517] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
192 Carvajal RD, Lawrence DP, Weber JS, Gajewski TF, Gonzalez R, Lutzky J, O'Day SJ, Hamid O, Wolchok JD, Chapman PB, Sullivan RJ, Teitcher JB, Ramaiya N, Giobbie-Hurder A, Antonescu CR, Heinrich MC, Bastian BC, Corless CL, Fletcher JA, Hodi FS. Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clin Cancer Res 2015;21:2289-96. [PMID: 25695690 DOI: 10.1158/1078-0432.CCR-14-1630] [Cited by in Crossref: 76] [Cited by in F6Publishing: 36] [Article Influence: 10.9] [Reference Citation Analysis]
193 Saponara M, Lolli C, Nannini M, DI Scioscio V, Serra C, Mandrioli A, Pallotti MC, Biasco G, Pantaleo MA. Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours. Oncol Lett 2014;8:1793-9. [PMID: 25202412 DOI: 10.3892/ol.2014.2348] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
194 Ferrari A, Patel SR, Wunder J, Albritton KH. Soft Tissue Sarcoma. In: Bleyer A, Barr R, Ries L, Whelan J, Ferrari A, editors. Cancer in Adolescents and Young Adults. Cham: Springer International Publishing; 2017. pp. 383-416. [DOI: 10.1007/978-3-319-33679-4_15] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
195 Lien IC, Pollack SM. Treatment of refractory gastrointestinal stromal tumor using pazopanib. Transl Gastroenterol Hepatol 2016;1:86. [PMID: 28138651 DOI: 10.21037/tgh.2016.11.01] [Reference Citation Analysis]
196 Judson I, Bulusu R, Seddon B, Dangoor A, Wong N, Mudan S. UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST). Clin Sarcoma Res. 2017;7:6. [PMID: 28465823 DOI: 10.1186/s13569-017-0072-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 7.2] [Reference Citation Analysis]
197 Mazzocca A, Napolitano A, Silletta M, Spalato Ceruso M, Santini D, Tonini G, Vincenzi B. New frontiers in the medical management of gastrointestinal stromal tumours. Ther Adv Med Oncol 2019;11:1758835919841946. [PMID: 31205499 DOI: 10.1177/1758835919841946] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
198 Kirsanov KI, Lesovaya EA, Fetisov TI, Bokhyan BY, Belitsky GA, Yakubovskaya MG. Current Approaches for Personalized Therapy of Soft Tissue Sarcomas. Sarcoma 2020;2020:6716742. [PMID: 32317857 DOI: 10.1155/2020/6716742] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
199 Deng GL, Zeng S, Shen H. Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges. World J Hepatol 2015; 7(5): 787-798 [PMID: 25914779 DOI: 10.4254/wjh.v7.i5.787] [Cited by in Crossref: 101] [Cited by in F6Publishing: 96] [Article Influence: 14.4] [Reference Citation Analysis]
200 Zeichner SB, Goldstein DA, Kohn C, Flowers CR. Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma. J Gastrointest Oncol 2017;8:513-23. [PMID: 28736638 DOI: 10.21037/jgo.2016.04.03] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
201 Romero-Espinosa L, Souza-Gallardo LM, Martínez-Ordaz JL, Romero-Hernández T, de la Fuente-Lira M, Arellano-Sotelo J. [Obscure gastrointestinal bleeding due to gastrointestinal stromal tumors]. Cir Cir 2017;85:214-9. [PMID: 27855991 DOI: 10.1016/j.circir.2016.09.006] [Reference Citation Analysis]
202 Rey JB, Launay-Vacher V, Tournigand C. Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists. Target Oncol 2015;10:199-213. [PMID: 25213039 DOI: 10.1007/s11523-014-0333-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
203 Winters AC, Bedier F, Saab S. Management of Side Effects of Systemic Therapies for Hepatocellular Carcinoma: Guide for the Hepatologist. Clin Liver Dis 2020;24:755-69. [PMID: 33012457 DOI: 10.1016/j.cld.2020.07.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
204 Hong S, Fang W, Liang W, Yan Y, Zhou T, Qin T, Wu X, Ma Y, Zhao Y, Yang Y, Hu Z, Xue C, Hou X, Chen Y, Huang Y, Zhao H, Zhang L. Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials. Onco Targets Ther 2014;7:1851-67. [PMID: 25336977 DOI: 10.2147/OTT.S68386] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
205 Wagner AJ, Severson PL, Shields AF, Patnaik A, Chugh R, Tinoco G, Wu G, Nespi M, Lin J, Zhang Y, Ewing T, Habets G, Burton EA, Matusow B, Tsai J, Tsang G, Shellooe R, Carias H, Chan K, Rezaei H, Sanftner L, Marimuthu A, Spevak W, Ibrahim PN, Inokuchi K, Alcantar O, Michelson G, Tsiatis AC, Zhang C, Bollag G, Trent JC, Tap WD. Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial. JAMA Oncol 2021. [PMID: 34236401 DOI: 10.1001/jamaoncol.2021.2086] [Reference Citation Analysis]
206 Schroeder B, Li Z, Cranmer LD, Jones RL, Pollack SM. Targeting gastrointestinal stromal tumors: the role of regorafenib. Onco Targets Ther 2016;9:3009-16. [PMID: 27284251 DOI: 10.2147/OTT.S104081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
207 Aggarwal A, Fojo T, Chamberlain C, Davis C, Sullivan R. Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund. Ann Oncol 2017;28:1738-50. [PMID: 28453615 DOI: 10.1093/annonc/mdx110] [Cited by in Crossref: 63] [Cited by in F6Publishing: 45] [Article Influence: 15.8] [Reference Citation Analysis]
208 Rinaldi L, Vetrano E, Rinaldi B, Galiero R, Caturano A, Salvatore T, Sasso FC. HCC and Molecular Targeting Therapies: Back to the Future. Biomedicines 2021;9:1345. [PMID: 34680462 DOI: 10.3390/biomedicines9101345] [Reference Citation Analysis]
209 Gatto L, Nannini M, Saponara M, Di Scioscio V, Beltramo G, Frezza GP, Ercolani G, Pinna AD, Astolfi A, Urbini M, Brandi G, Biasco G, Pantaleo MA. Radiotherapy in the management of gist: state of the art and new potential scenarios. Clin Sarcoma Res 2017;7:1. [PMID: 28078078 DOI: 10.1186/s13569-016-0065-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
210 Battisti NML, Decoster L, Williams GR, Kanesvaran R, Wildiers H, Ring A. Targeted Therapies in Older Adults With Solid Tumors. J Clin Oncol 2021;39:2128-37. [PMID: 34043448 DOI: 10.1200/JCO.21.00132] [Reference Citation Analysis]
211 Lim Y, Han SW, Yoon JH, Lee JM, Lee JM, Paeng JC, Won JK, Kang GH, Jeong SY, Park KJ, Lee KH, Kim JH, Kim TY. Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer. PLoS One 2015;10:e0145004. [PMID: 26671465 DOI: 10.1371/journal.pone.0145004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
212 Lubberman FJE, van der Graaf WTA, Xu L, Cleton A, Demetri GD, Gelderblom H, van Erp NP. The effect of gastrectomy on regorafenib exposure and progression-free survival in patients with advanced gastrointestinal stromal tumours. Br J Clin Pharmacol 2019;85:2399-404. [PMID: 31290566 DOI: 10.1111/bcp.14061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
213 Nguyen K, Jack K, Sun W. Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy. Diseases 2015;4:E1. [PMID: 28933381 DOI: 10.3390/diseases4010001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
214 Zhang G, Kodani S, Hammock BD. Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer. Prog Lipid Res 2014;53:108-23. [PMID: 24345640 DOI: 10.1016/j.plipres.2013.11.003] [Cited by in Crossref: 98] [Cited by in F6Publishing: 92] [Article Influence: 10.9] [Reference Citation Analysis]
215 Janku F, Abdul Razak AR, Chi P, Heinrich MC, von Mehren M, Jones RL, Ganjoo K, Trent J, Gelderblom H, Somaiah N, Hu S, Rosen O, Su Y, Ruiz-Soto R, Gordon M, George S. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. J Clin Oncol 2020;38:3294-303. [PMID: 32804590 DOI: 10.1200/JCO.20.00522] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 9.5] [Reference Citation Analysis]
216 Berretta M, Rinaldi L, Di Benedetto F, Lleshi A, De Re V, Facchini G, De Paoli P, Di Francia R. Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma. Front Pharmacol 2016;7:428. [PMID: 27881963 DOI: 10.3389/fphar.2016.00428] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
217 Boichuk S, Galembikova A, Mikheeva E, Bikinieva F, Aukhadieva A, Dunaev P, Khalikov D, Petrov S, Kurtasanov R, Valeeva E, Kireev I, Dugina V, Lushnikova A, Novikova M, Kopnin P. Inhibition of FGF2-Mediated Signaling in GIST-Promising Approach for Overcoming Resistance to Imatinib. Cancers (Basel) 2020;12:E1674. [PMID: 32599808 DOI: 10.3390/cancers12061674] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
218 Saharinen P, Eklund L, Alitalo K. Therapeutic targeting of the angiopoietin-TIE pathway. Nat Rev Drug Discov 2017;16:635-61. [PMID: 28529319 DOI: 10.1038/nrd.2016.278] [Cited by in Crossref: 176] [Cited by in F6Publishing: 161] [Article Influence: 35.2] [Reference Citation Analysis]
219 Duan Y, Haybaeck J, Yang Z. Therapeutic Potential of PI3K/AKT/mTOR Pathway in Gastrointestinal Stromal Tumors: Rationale and Progress. Cancers (Basel) 2020;12:E2972. [PMID: 33066449 DOI: 10.3390/cancers12102972] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
220 Munster PN. More Options for Fertility Preservation for Patients With Cancer. J Clin Oncol 2015;33:2413-5. [PMID: 26101241 DOI: 10.1200/JCO.2015.61.9304] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
221 Prasad V, Massey PR, Fojo T. Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J Clin Oncol 2014;32:1620-9. [PMID: 24711558 DOI: 10.1200/JCO.2013.53.0204] [Cited by in Crossref: 39] [Cited by in F6Publishing: 13] [Article Influence: 4.9] [Reference Citation Analysis]
222 Nagatani Y, Shitara K, Bando H, Kuboki Y, Okamoto W, Kojima T, Yoshino T, Nishida T, Ohtsu A, Doi T. Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials. BMC Cancer 2016;16:889. [PMID: 27842521 DOI: 10.1186/s12885-016-2939-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
223 Chen D, Wei L, Yu J, Zhang L. Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis. Clin Cancer Res 2014;20:3472-84. [PMID: 24763611 DOI: 10.1158/1078-0432.CCR-13-2944] [Cited by in Crossref: 65] [Cited by in F6Publishing: 50] [Article Influence: 8.1] [Reference Citation Analysis]
224 Ocana A, Ethier JL, Díez-González L, Corrales-Sánchez V, Srikanthan A, Gascón-Escribano MJ, Templeton AJ, Vera-Badillo F, Seruga B, Niraula S, Pandiella A, Amir E. Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. Oncotarget 2015;6:39538-49. [PMID: 26446908 DOI: 10.18632/oncotarget.5946] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
225 Hsueh YS, Chang HH, Chiang NJ, Yen CC, Li CF, Chen LT. MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors. Oncotarget 2014;5:11723-36. [PMID: 25375091 DOI: 10.18632/oncotarget.2607] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
226 Ma C, Yin H, Zhong J, Zhang Y, Luo C, Che D, Fang Z, Li L, Qin S, Liang J, Qi W, Yang Z, Zhou T, Ma J, Yang X, Gao G. Kallistatin exerts anti-lymphangiogenic effects by inhibiting lymphatic endothelial cell proliferation, migration and tube formation. Int J Oncol 2017;50:2000-10. [PMID: 28440474 DOI: 10.3892/ijo.2017.3972] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
227 Serrano C, Vivancos A, López-Pousa A, Matito J, Mancuso FM, Valverde C, Quiroga S, Landolfi S, Castro S, Dopazo C, Sebio A, Virgili AC, Menso MM, Martín-Broto J, Sansó M, García-Valverde A, Rosell J, Fletcher JA, George S, Carles J, Arribas J. Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors. BMC Cancer 2020;20:99. [PMID: 32024476 DOI: 10.1186/s12885-020-6597-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
228 Grellety T, Kind M, Coindre JM, Italiano A. Clinical activity of regorafenib in PDGFRA-mutated gastrointestinal stromal tumor. Future Sci OA 2015;1:FSO33. [PMID: 28031906 DOI: 10.4155/fso.15.33] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
229 Schroeder BA, Kohli K, O'Malley RB, Kim TS, Jones RL, Pierce RH, Pollack SM. Durable tumor regression in highly refractory metastatic KIT/PDGFRA wild-type GIST following treatment with nivolumab. Oncoimmunology 2020;9:1710064. [PMID: 32002307 DOI: 10.1080/2162402X.2019.1710064] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
230 Hellmann MD, Sturm I, Trnkova ZJ, Lettieri J, Diefenbach K, Rizvi NA, Gettinger SN. Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers. Clin Lung Cancer 2015;16:514-22. [PMID: 26003007 DOI: 10.1016/j.cllc.2015.04.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
231 Zhou Y, Zhang X, Wu X, Zhou Y, Zhang B, Liu X, Wu X, Li Y, Shen L, Li J. A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood. Cancer Med 2020;9:6225-33. [PMID: 32677196 DOI: 10.1002/cam4.3319] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
232 Carlson J, Alobuia W, Mizell J. Rectal gastrointestinal stromal tumor with metastasis to the penis: Case report and review of literature. Int J Surg Case Rep 2016;29:172-5. [PMID: 27865145 DOI: 10.1016/j.ijscr.2016.11.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
233 Zalcberg JR. Ripretinib for the treatment of advanced gastrointestinal stromal tumor. Therap Adv Gastroenterol 2021;14:17562848211008177. [PMID: 33948116 DOI: 10.1177/17562848211008177] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
234 Patel SR, Reichardt P. An updated review of the treatment landscape for advanced gastrointestinal stromal tumors. Cancer 2021;127:2187-95. [PMID: 33974733 DOI: 10.1002/cncr.33630] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
235 Jiang X, Pissaloux D, De La Fouchardiere C, Desseigne F, Wang Q, Attignon V, Fondrevelle ME, De La Fouchardiere A, Perol M, Cassier P, Seigne C, Perol D, Ray-Coquard I, Meeus P, Fayette J, Flechon A, Le Cesne A, Penel N, Tredan O, Blay JY. The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value. Oncotarget 2015;6:26388-99. [PMID: 26317543 DOI: 10.18632/oncotarget.4557] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
236 Tapia Rico G, Townsend AR, Broadbridge V, Price TJ. Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence. Drugs Aging 2017;34:173-89. [PMID: 28197947 DOI: 10.1007/s40266-017-0439-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
237 Belum VR, Marulanda K, Ensslin C, Gorcey L, Parikh T, Wu S, Busam KJ, Gerber PA, Lacouture ME. Alopecia in patients treated with molecularly targeted anticancer therapies. Ann Oncol 2015;26:2496-502. [PMID: 26387145 DOI: 10.1093/annonc/mdv390] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
238 Gelderblom H, Jones RL, George S, Valverde Morales C, Benson C, Jean-Yves Blay, Renouf DJ, Doi T, Le Cesne A, Leahy M, Hertle S, Aimone P, Brandt U, Schӧffski P. Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study. Br J Cancer 2020;122:1158-65. [PMID: 32147671 DOI: 10.1038/s41416-020-0769-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
239 Yavropoulou MP, Gerothanasi N, Frydas A, Triantafyllou E, Poulios C, Hytiroglou P, Apostolou P, Papasotiriou I, Tournis S, Kesisoglou I, Yovos JG. Tumor-induced osteomalacia due to a recurrent mesenchymal tumor overexpressing several growth factor receptors. Endocrinol Diabetes Metab Case Rep 2015;2015:150025. [PMID: 26155363 DOI: 10.1530/EDM-15-0025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
240 Park SR, Ryu MH, Ryoo BY, Beck MY, Lee IS, Choi MJ, Lee MW, Kang YK. Severe Imatinib-Associated Skin Rash in Gastrointestinal Stromal Tumor Patients: Management and Clinical Implications. Cancer Res Treat 2016;48:162-70. [PMID: 26323636 DOI: 10.4143/crt.2015.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
241 Gillis NK, McLeod HL. The pharmacogenomics of drug resistance to protein kinase inhibitors. Drug Resist Updat 2016;28:28-42. [PMID: 27620953 DOI: 10.1016/j.drup.2016.06.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
242 Bauer S, Joensuu H. Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions. Drugs 2015;75:1323-34. [PMID: 26187774 DOI: 10.1007/s40265-015-0440-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
243 Daudigeos-Dubus E, Le Dret L, Lanvers-Kaminsky C, Bawa O, Opolon P, Vievard A, Villa I, Pagès M, Bosq J, Vassal G, Zopf D, Geoerger B. Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models. PLoS One 2015;10:e0142612. [PMID: 26599335 DOI: 10.1371/journal.pone.0142612] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
244 Jiang X, Anderson HB, Guy CD, Mosca PJ, Riedel RF, Cardona DM. Rhabdomyosarcomatous Transformation of a Gastrointestinal Stromal Tumor following Treatment with Imatinib. Case Rep Oncol Med 2015;2015:317493. [PMID: 25694839 DOI: 10.1155/2015/317493] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
245 Riechelmann RP, Leite LS, Bariani GM, Glasberg J, Rivelli TG, da Fonseca LG, Nebuloni DR, Braghiroli MI, Queiroz MA, Isejima AM, Kappeler C, Kikuchi L, Hoff PM. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial. Oncologist 2019;24:1180-7. [PMID: 31175167 DOI: 10.1634/theoncologist.2019-0067] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
246 Kim JJ, Lim JY, Nguyen SQ. Laparoscopic resection of gastrointestinal stromal tumors: Does laparoscopic surgery provide an adequate oncologic resection? World J Gastrointest Endosc 2017; 9(9): 448-455 [PMID: 28979709 DOI: 10.4253/wjge.v9.i9.448] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
247 Bronte E, Bronte G, Novo G, Bronte F, Bavetta MG, Lo Re G, Brancatelli G, Bazan V, Natoli C, Novo S, Russo A. What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment. Oncotarget 2015;6:35589-601. [PMID: 26431495 DOI: 10.18632/oncotarget.5853] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
248 Komatsu Y, Doi T, Sawaki A, Kanda T, Yamada Y, Kuss I, Demetri GD, Nishida T. Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial. Int J Clin Oncol 2015;20:905-12. [PMID: 25655899 DOI: 10.1007/s10147-015-0790-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
249 Kikuchi H, Hiramatsu Y, Kamiya K, Morita Y, Sakaguchi T, Konno H, Takeuchi H. Surgery for metastatic gastrointestinal stromal tumor: to whom and how to? Transl Gastroenterol Hepatol 2018;3:14. [PMID: 29682621 DOI: 10.21037/tgh.2018.02.02] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
250 Prieto-Potin I, Carvajal N, Plaza-Sánchez J, Manso R, Aúz-Alexandre CL, Chamizo C, Zazo S, López-Sánchez A, Rodríguez-Pinilla SM, Camacho L, Longarón R, Bellosillo B, Somoza R, Hernández-Losa J, Fernández-Soria VM, Ramos-Ruiz R, Cristóbal I, García-Foncillas J, Rojo F. Validation and clinical application of a targeted next-generation sequencing gene panel for solid and hematologic malignancies. PeerJ 2020;8:e10069. [PMID: 33083132 DOI: 10.7717/peerj.10069] [Reference Citation Analysis]
251 Hemming ML, Lawlor MA, Andersen JL, Hagan T, Chipashvili O, Scott TG, Raut CP, Sicinska E, Armstrong SA, Demetri GD, Bradner JE. Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition. Cancer Res. 2019;79:994-1009. [PMID: 30630822 DOI: 10.1158/0008-5472] [Cited by in F6Publishing: 161] [Reference Citation Analysis]
252 Huang L, Jiang S, Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). J Hematol Oncol 2020;13:143. [PMID: 33109256 DOI: 10.1186/s13045-020-00977-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
253 Clarke JM, Hurwitz HI. Understanding and targeting resistance to anti-angiogenic therapies. J Gastrointest Oncol. 2013;4:253-263. [PMID: 23997938 DOI: 10.3978/j.issn.2078-6891.2013.036] [Cited by in F6Publishing: 39] [Reference Citation Analysis]
254 Doleschel D, Hoff S, Koletnik S, Rix A, Zopf D, Kiessling F, Lederle W. Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth. J Exp Clin Cancer Res 2021;40:288. [PMID: 34517894 DOI: 10.1186/s13046-021-02043-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
255 Son MK, Ryu MH, Park JO, Im SA, Kim TY, Lee SJ, Ryoo BY, Park SR, Kang YK. Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program. Cancer Res Treat 2017;49:350-7. [PMID: 27456941 DOI: 10.4143/crt.2016.067] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
256 Pande N, Shetty O, Boppana M, Ramaswamy A, Saklani A, Shetty N, Ostwal V. Pazopanib use preceding curative surgery in low rectal gastrointestinal stromal tumors after imatinib failure: A case report. South Asian J Cancer 2019;8:51. [PMID: 30766855 DOI: 10.4103/sajc.sajc_183_18] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
257 Serrano C, George S, Valverde C, Olivares D, García-Valverde A, Suárez C, Morales-Barrera R, Carles J. Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors. Target Oncol 2017;12:277-88. [PMID: 28478525 DOI: 10.1007/s11523-017-0490-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
258 Platoff RM, Morano WF, Marconcini L, DeLeo N, Mapow BL, Styler M, Bowne WB. Recurrent Gastrointestinal Stromal Tumors in the Imatinib Mesylate Era: Treatment Strategies for an Incurable Disease. Case Rep Oncol Med 2017;2017:8349090. [PMID: 29333308 DOI: 10.1155/2017/8349090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
259 Farag S, Smith MJ, Fotiadis N, Constantinidou A, Jones RL. Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates. Curr Treat Options Oncol 2020;21:55. [PMID: 32462367 DOI: 10.1007/s11864-020-00754-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
260 Rausch JL, Ali AA, Lee DM, Gebreyohannes YK, Mehalek KR, Agha A, Patil SS, Tolstov Y, Wellens J, Dhillon HS, Makielski KR, Debiec-Rychter M, Schöffski P, Wozniak A, Duensing A. Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells. Sci Rep 2020;10:5178. [PMID: 32198455 DOI: 10.1038/s41598-020-62088-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
261 Wu L, Zhang Z, Yao H, Liu K, Wen Y, Xiong L. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials. Drug Des Devel Ther. 2014;8:2061-2067. [PMID: 25378911 DOI: 10.2147/dddt.s63840] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
262 Schvartsman G, Wagner MJ, Zobniw CM, Trinh VA, Patel S, Somaiah N. An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients. Curr Oncol Rep 2016;18:49. [PMID: 27319943 DOI: 10.1007/s11912-016-0536-7] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
263 Procaccio L, Damuzzo V, Di Sarra F, Russi A, Todino F, Dadduzio V, Bergamo F, Prete AA, Lonardi S, Prenen H, Palozzo AC, Loupakis F. Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies. Drug Saf 2019;42:159-79. [PMID: 30649744 DOI: 10.1007/s40264-018-0776-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
264 Raissouni S, Quraishi Z, Al-Ghamdi M, Monzon J, Tang P, Vickers MM. Acute liver failure and seizures as a consequence of regorafenib exposure in advanced rectal cancer. BMC Res Notes 2015;8:538. [PMID: 26438070 DOI: 10.1186/s13104-015-1502-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
265 Antonescu CR, DeMatteo RP. CCR 20th Anniversary Commentary: A Genetic Mechanism of Imatinib Resistance in Gastrointestinal Stromal Tumor-Where Are We a Decade Later? Clin Cancer Res 2015;21:3363-5. [PMID: 26240289 DOI: 10.1158/1078-0432.CCR-14-3120] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
266 Wang Y, Chen W, Shi Y, Yan C, Kong Z, Wang Y, Wang Y, Ma W. Imposing Phase II and Phase III Clinical Trials of Targeted Drugs for Glioblastoma: Current Status and Progress. Front Oncol 2021;11:719623. [PMID: 34568049 DOI: 10.3389/fonc.2021.719623] [Reference Citation Analysis]
267 Serrano C, George S. Recent advances in the treatment of gastrointestinal stromal tumors. Ther Adv Med Oncol 2014;6:115-27. [PMID: 24790651 DOI: 10.1177/1758834014522491] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 5.5] [Reference Citation Analysis]
268 Hashemi-Sadraei N, Hanna N. Targeting FGFR in Squamous Cell Carcinoma of the Lung. Target Oncol 2017;12:741-55. [PMID: 28685321 DOI: 10.1007/s11523-017-0513-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
269 Galati G, Massimo Vainieri AF, Maria Fulgenzi CA, Di Donato S, Silletta M, Gallo P, Onorato A, Vespasiani-Gentilucci U, Picardi A. Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis. Curr Drug Metab 2020;21:866-84. [PMID: 32957880 DOI: 10.2174/1389200221999200918141239] [Reference Citation Analysis]
270 Hattori E, Oyama R, Kondo T. Systematic Review of the Current Status of Human Sarcoma Cell Lines. Cells 2019;8:E157. [PMID: 30781855 DOI: 10.3390/cells8020157] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
271 Nakano K, Takahashi S. Precision Medicine in Soft Tissue Sarcoma Treatment. Cancers (Basel) 2020;12:E221. [PMID: 31963219 DOI: 10.3390/cancers12010221] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
272 Kelly CM, Shoushtari AN, Qin LX, D'Angelo SP, Dickson MA, Gounder MM, Keohan ML, Mcfadyen C, Sjoberg A, Singer S, DeMatteo RP, Hwang S, Heinemann MH, Francis JH, Antonescu CR, Chi P, Tap WD. A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. Invest New Drugs 2019;37:282-90. [PMID: 30101387 DOI: 10.1007/s10637-018-0648-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
273 Awad MM, Katayama R, McTigue M, Liu W, Deng YL, Brooun A, Friboulet L, Huang D, Falk MD, Timofeevski S. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med. 2013;368:2395-2401. [PMID: 23724914 DOI: 10.1056/nejmoa1215530] [Cited by in Crossref: 232] [Cited by in F6Publishing: 112] [Article Influence: 25.8] [Reference Citation Analysis]
274 Sjoquist KM, Zalcberg JR. Gastric cancer: past progress and present challenges. Gastric Cancer 2015;18:205-9. [PMID: 25344928 DOI: 10.1007/s10120-014-0437-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
275 Amirnasr A, Sleijfer S, Wiemer EAC. Non-Coding RNAs, a Novel Paradigm for the Management of Gastrointestinal Stromal Tumors. Int J Mol Sci 2020;21:E6975. [PMID: 32972022 DOI: 10.3390/ijms21186975] [Reference Citation Analysis]
276 Liu F, Zou F, Chen C, Yu K, Liu X, Qi S, Wu J, Hu C, Hu Z, Liu J, Liu X, Wang L, Ge J, Wang W, Ren T, Bai M, Cai Y, Xiao X, Qian F, Tang J, Liu Q, Liu J. Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors. Ther Adv Med Oncol 2019;11:1758835919849757. [PMID: 31205508 DOI: 10.1177/1758835919849757] [Reference Citation Analysis]
277 Yeh CN. Response letter on Micromanagement of drug-resistant advanced gastrointestinal stromal tumors: regorafenib-new ammunition in battling exon 17 mutations. Transl Gastroenterol Hepatol 2018;3:33. [PMID: 30050993 DOI: 10.21037/tgh.2018.06.03] [Reference Citation Analysis]
278 George S, Jones RL, Bauer S, Kang YK, Schöffski P, Eskens F, Mir O, Cassier PA, Serrano C, Tap WD, Trent J, Rutkowski P, Patel S, Chawla SP, Meiri E, Gordon M, Zhou T, Roche M, Heinrich MC, von Mehren M. Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. Oncologist 2021;26:e639-49. [PMID: 33453089 DOI: 10.1002/onco.13674] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
279 Proudman D, Miller A, Nellesen D, Gomes A, Mankoski R, Norregaard C, Sullivan E. Financial Implications of Avapritinib for Treatment of Unresectable Gastrointestinal Stromal Tumors in Patients With a PDGFRA Exon 18 Variant or After 3 Previous Therapies in a Hypothetical US Health Plan. JAMA Netw Open 2020;3:e2025866. [PMID: 33201235 DOI: 10.1001/jamanetworkopen.2020.25866] [Reference Citation Analysis]
280 Di Francia R, Berretta M, Benincasa G, D'Avino A, Facchini S, Costagliola D, Rossi P. Pharmacogenetic-Based Interactions between Nutraceuticals and Angiogenesis Inhibitors. Cells 2019;8:E522. [PMID: 31151284 DOI: 10.3390/cells8060522] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
281 Hickey R, Vouche M, Sze DY, Hohlastos E, Collins J, Schirmang T, Memon K, Ryu RK, Sato K, Chen R, Gupta R, Resnick S, Carr J, Chrisman HB, Nemcek AA Jr, Vogelzang RL, Lewandowski RJ, Salem R. Cancer concepts and principles: primer for the interventional oncologist-part II. J Vasc Interv Radiol 2013;24:1167-88. [PMID: 23810312 DOI: 10.1016/j.jvir.2013.04.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
282 Reichardt P. [Soft tissue sarcomas and gastrointestinal stromal tumors]. Internist (Berl) 2016;57:245-56. [PMID: 26907871 DOI: 10.1007/s00108-016-0021-2] [Reference Citation Analysis]
283 Jakhetiya A, Garg PK, Prakash G, Sharma J, Pandey R, Pandey D. Targeted therapy of gastrointestinal stromal tumours. World J Gastrointest Surg 2016; 8(5): 345-352 [PMID: 27231512 DOI: 10.4240/wjgs.v8.i5.345] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
284 Annan DA, Kikuchi H, Maishi N, Hida Y, Hida K. Tumor Endothelial Cell-A Biological Tool for Translational Cancer Research. Int J Mol Sci 2020;21:E3238. [PMID: 32375250 DOI: 10.3390/ijms21093238] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
285 Sako H, Fukuda K, Saikawa Y, Nakamura R, Takahashi T, Wada N, Kawakubo H, Takeuchi H, Ohmori T, Kitagawa Y. Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells. PLoS One 2014;9:e107613. [PMID: 25221952 DOI: 10.1371/journal.pone.0107613] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
286 Fondevila F, Méndez-Blanco C, Fernández-Palanca P, González-Gallego J, Mauriz JL. Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers. Exp Mol Med 2019;51:1-15. [PMID: 31551425 DOI: 10.1038/s12276-019-0308-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
287 Koo DH, Ryu MH, Kim KM, Yang HK, Sawaki A, Hirota S, Zheng J, Zhang B, Tzen CY, Yeh CN, Nishida T, Shen L, Chen LT, Kang YK. Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor. Cancer Res Treat. 2016;48:1155-1166. [PMID: 27384163 DOI: 10.4143/crt.2016.187] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 10.5] [Reference Citation Analysis]
288 Liu J, Deng YT, Wu X, Jiang Y. Rechallenge with Multi-Targeted Tyrosine Kinase Inhibitors in Patients with Advanced Soft Tissue Sarcoma: A Single-Center Experience. Cancer Manag Res 2021;13:2595-601. [PMID: 33776477 DOI: 10.2147/CMAR.S300430] [Reference Citation Analysis]
289 Huynh H, Ong R, Zopf D. Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer. J Exp Clin Cancer Res. 2015;34:132. [PMID: 26514182 DOI: 10.1186/s13046-015-0243-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
290 Zuidema S, Desar IME, van Erp NP, Kievit W. Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness study. Br J Clin Pharmacol 2019;85:1994-2001. [PMID: 31112617 DOI: 10.1111/bcp.13990] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
291 Taguchi D, Inoue M, Fukuda K, Yoshida T, Shimazu K, Fujita K, Okuyama H, Matsuhashi N, Tsuji A, Yoshida K, Miura M, Shibata H. Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities. Int J Clin Oncol 2020;25:531-40. [PMID: 31807967 DOI: 10.1007/s10147-019-01593-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
292 Call JW, Wang Y, Montoya D, Scherzer NJ, Heinrich MC. Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry. Clin Sarcoma Res 2019;9:4. [PMID: 30984366 DOI: 10.1186/s13569-019-0114-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
293 Chen HW, Chen TW. Genomic-guided precision therapy for soft tissue sarcoma. ESMO Open 2020;5:e000626. [PMID: 32132106 DOI: 10.1136/esmoopen-2019-000626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
294 Pantaleo MA, Tarantino G, Agostinelli C, Urbini M, Nannini M, Saponara M, Castelli C, Stacchiotti S, Fumagalli E, Gatto L, Santini D, De Leo A, Marafioti T, Akarca A, Sabattini E, Pession A, Ardizzoni A, Indio V, Astolfi A. Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response. Oncoimmunology 2019;8:e1617588. [PMID: 31428517 DOI: 10.1080/2162402X.2019.1617588] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
295 Shirley M, Keating GM. Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours. Drugs 2015;75:1009-17. [PMID: 25998375 DOI: 10.1007/s40265-015-0406-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
296 Vitiello GA, Medina BD, Zeng S, Bowler TG, Zhang JQ, Loo JK, Param NJ, Liu M, Moral AJ, Zhao JN, Rossi F, Antonescu CR, Balachandran VP, Cross JR, DeMatteo RP. Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor. Clin Cancer Res. 2018;24:972-984. [PMID: 29246941 DOI: 10.1158/1078-0432.ccr-17-2697] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
297 Dudzisz-Śledź M, Bylina E, Teterycz P, Rutkowski P. Treatment of Metastatic Gastrointestinal Stromal Tumors (GIST): A Focus on Older Patients. Drugs Aging 2021;38:375-96. [PMID: 33651369 DOI: 10.1007/s40266-021-00841-x] [Reference Citation Analysis]
298 Saavedra E, Hollebecque A, Soria JC, Hartl DM. Dysphonia induced by anti-angiogenic compounds. Invest New Drugs 2014;32:774-82. [PMID: 24343672 DOI: 10.1007/s10637-013-0049-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
299 Kuwayama M, Uchino K, Takayoshi K, Komoda M, Kohjima M, Nakamuta M, Momosaki S, Kusaba H, Akashi K, Baba E. Immunosuppressant therapy successfully improved regorafenib-induced severe hepatic injury in a patient with metastatic gastrointestinal stromal tumor: A case report. Oncol Lett 2016;11:85-8. [PMID: 26870172 DOI: 10.3892/ol.2015.3853] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
300 Zhao R, Song Y, Wang Y, Huang Y, Li Z, Cui Y, Yi M, Xia L, Zhuang W, Wu X, Zhou Y. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway. Cell Prolif 2019;52:e12571. [PMID: 30714229 DOI: 10.1111/cpr.12571] [Cited by in Crossref: 29] [Cited by in F6Publishing: 36] [Article Influence: 9.7] [Reference Citation Analysis]
301 Kaczmarska A, Śliwa P, Lejman M, Zawitkowska J. The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology-When and Why? Int J Mol Sci 2021;22:12089. [PMID: 34769519 DOI: 10.3390/ijms222112089] [Reference Citation Analysis]
302 Tian Z, Niu X, Yao W. Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target? Front Oncol 2020;10:1642. [PMID: 32984034 DOI: 10.3389/fonc.2020.01642] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
303 Aprile G, Bonotto M, Ongaro E, Pozzo C, Giuliani F. Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use. Drugs. 2013;73:2003-2015. [PMID: 24277700 DOI: 10.1007/s40265-013-0154-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
304 Tsai AK, Khan AY, Worgo CE, Wang LL, Liang Y, Davila E. A Multikinase and DNA-PK Inhibitor Combination Immunomodulates Melanomas, Suppresses Tumor Progression, and Enhances Immunotherapies. Cancer Immunol Res 2017;5:790-803. [PMID: 28775208 DOI: 10.1158/2326-6066.CIR-17-0009] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
305 Andreuzzi E, Capuano A, Poletto E, Pivetta E, Fejza A, Favero A, Doliana R, Cannizzaro R, Spessotto P, Mongiat M. Role of Extracellular Matrix in Gastrointestinal Cancer-Associated Angiogenesis. Int J Mol Sci 2020;21:E3686. [PMID: 32456248 DOI: 10.3390/ijms21103686] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
306 Zhao Y, Adjei AA. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor. Oncologist 2015;20:660-73. [PMID: 26001391 DOI: 10.1634/theoncologist.2014-0465] [Cited by in Crossref: 266] [Cited by in F6Publishing: 254] [Article Influence: 38.0] [Reference Citation Analysis]
307 Tirumani SH, Baheti AD, Tirumani H, O'Neill A, Jagannathan JP. Update on Gastrointestinal Stromal Tumors for Radiologists. Korean J Radiol 2017;18:84-93. [PMID: 28096720 DOI: 10.3348/kjr.2017.18.1.84] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
308 Boichuk S, Galembikova A, Dunaev P, Valeeva E, Shagimardanova E, Gusev O, Khaiboullina S. A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance. Molecules 2017;22:E2152. [PMID: 29206199 DOI: 10.3390/molecules22122152] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
309 Kitade H, Hiromasa-Yamasaki A, Hokkoku K, Mori M, Watanabe M, Nakai M, Yano S. Elevated prothrombin time/international normalized ratio associated with concurrent administration of regorafenib and warfarin in a patient with advanced colorectal cancer. J Pharm Health Care Sci 2016;2:15. [PMID: 27398225 DOI: 10.1186/s40780-016-0050-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
310 Smyth EC. Regorafenib in gastric cancer. Transl Gastroenterol Hepatol 2017;2:16. [PMID: 28447051 DOI: 10.21037/tgh.2017.01.07] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
311 Yeh CN, Yen CC, Chen YY, Cheng CT, Huang SC, Chang TW, Yao FY, Lin YC, Wen YS, Chiang KC, Chen JS, Yeh TS, Tzeng CH, Chao TC, Fletcher JA. Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumors. Oncotarget 2014;5:4071-86. [PMID: 24901229 DOI: 10.18632/oncotarget.1705] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
312 Trojan J, Waidmann O. Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma. J Hepatocell Carcinoma. 2016;3:31-36. [PMID: 27703962 DOI: 10.2147/jhc.s112537] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
313 Astolfi A, Pantaleo MA, Indio V, Urbini M, Nannini M. The Emerging Role of the FGF/FGFR Pathway in Gastrointestinal Stromal Tumor. Int J Mol Sci 2020;21:E3313. [PMID: 32392832 DOI: 10.3390/ijms21093313] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
314 Kim RD, Sanoff HK, Poklepovic AS, Soares H, Kim J, Lyu J, Liu Y, Nixon AB, Kim DW. A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer. Cancer 2020;126:3464-70. [PMID: 32453456 DOI: 10.1002/cncr.32964] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
315 Cho H, Ryu MH, Lee Y, Park YS, Kim KH, Kim JH, Park Y, Lee SM, Kim CW, Kim BS, Yoo MW, Kang YK. Role of Resection Following Focal Progression with Standard Doses of Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses. Oncologist 2019;24:e1443-9. [PMID: 31315961 DOI: 10.1634/theoncologist.2019-0009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
316 Li GZ, Raut CP. Targeted therapy and personalized medicine in gastrointestinal stromal tumors: drug resistance, mechanisms, and treatment strategies. Onco Targets Ther 2019;12:5123-33. [PMID: 31308690 DOI: 10.2147/OTT.S180763] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 5.3] [Reference Citation Analysis]
317 Vincenzi B, Nannini M, Fumagalli E, Bronte G, Frezza AM, De Lisi D, Spalato Ceruso M, Santini D, Badalamenti G, Pantaleo MA, Russo A, Dei Tos AP, Casali P, Tonini G. Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. Oncotarget 2016;7:69412-9. [PMID: 26416414 DOI: 10.18632/oncotarget.5136] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
318 Ravegnini G, Sammarini G, Moran S, Calice G, Indio V, Urbini M, Astolfi A, Zanotti F, Pantaleo MA, Hrelia P, Angelini S. Mechanisms of resistance to a PI3K inhibitor in gastrointestinal stromal tumors: an omic approach to identify novel druggable targets. Cancer Manag Res 2019;11:6229-44. [PMID: 31308757 DOI: 10.2147/CMAR.S189661] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
319 Galun D, Srdic-Rajic T, Bogdanovic A, Loncar Z, Zuvela M. Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies. J Hepatocell Carcinoma 2017;4:93-103. [PMID: 28744453 DOI: 10.2147/JHC.S106529] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
320 Garlipp B, Bruns CJ. State of the Art in the Treatment of Gastrointestinal Stromal Tumors. Gastrointest Tumors 2014;1:221-36. [PMID: 26672673 DOI: 10.1159/000380788] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
321 Wong RJ, Longacre TA, Poultsides G, Park W, Rothenberg ME. Gastrointestinal stromal tumor: an unusual cause of gastrointestinal bleeding. Dig Dis Sci 2013;58:3112-6. [PMID: 23633157 DOI: 10.1007/s10620-013-2678-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
322 Ran L, Sirota I, Cao Z, Murphy D, Chen Y, Shukla S, Xie Y, Kaufmann MC, Gao D, Zhu S. Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumour growth. Canc Discov. 2015;5:304-315. [PMID: 25572173 DOI: 10.1158/2159-8290.cd-14-0985] [Cited by in Crossref: 66] [Cited by in F6Publishing: 47] [Article Influence: 9.4] [Reference Citation Analysis]
323 Xu K, He Z, Chen M, Wang N, Zhang D, Yang L, Xu Z, Xu H. HIF-1α regulates cellular metabolism, and Imatinib resistance by targeting phosphogluconate dehydrogenase in gastrointestinal stromal tumors. Cell Death Dis 2020;11:586. [PMID: 32719331 DOI: 10.1038/s41419-020-02768-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
324 Spitaleri G, Biffi R, Barberis M, Fumagalli C, Toffalorio F, Catania C, Noberasco C, Lazzari C, de Marinis F, De Pas T. Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K). Onco Targets Ther 2015;8:1997-2003. [PMID: 26316776 DOI: 10.2147/OTT.S81558] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
325 Orita H, Ito T, Kushida T, Sakurada M, Maekawa H, Wada R, Suehara Y, Kubota D, Sato K. Pfetin as a risk factor of recurrence in gastrointestinal stromal tumors. Biomed Res Int 2014;2014:651935. [PMID: 24977158 DOI: 10.1155/2014/651935] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
326 Lin Q, Tao P, Wang J, Ma L, Jiang Q, Li J, Zhang G, Liu J, Zhang Y, Hou Y, Lu W, Xue R, Tong H. Tumor-associated tertiary lymphoid structure predicts postoperative outcomes in patients with primary gastrointestinal stromal tumors. Oncoimmunology 2020;9:1747339. [PMID: 32313726 DOI: 10.1080/2162402X.2020.1747339] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
327 Kaliks RA. An update on clinical oncology for the non-oncologist. Einstein (Sao Paulo) 2016;14:294-9. [PMID: 27462901 DOI: 10.1590/S1679-45082016MD3550] [Reference Citation Analysis]
328 Qin S, Li A, Yi M, Yu S, Zhang M, Wu K. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol Oncol 2019;12:27. [PMID: 30866992 DOI: 10.1186/s13045-019-0718-5] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 23.7] [Reference Citation Analysis]
329 Hensley H, Devarajan K, Johnson JR, Piwnica-Worms D, Godwin AK, von Mehren M, Rink L. Evaluating new therapies in gastrointestinal stromal tumor using in vivo molecular optical imaging. Cancer Biol Ther 2014;15:911-8. [PMID: 24755645 DOI: 10.4161/cbt.28880] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
330 Belum VR, Wu S, Lacouture ME. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. Invest New Drugs. 2013;31:1078-1086. [PMID: 23700287 DOI: 10.1007/s10637-013-9977-0] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 6.1] [Reference Citation Analysis]
331 von Mehren M, Joensuu H. Gastrointestinal Stromal Tumors. J Clin Oncol. 2018;36:136-143. [PMID: 29220298 DOI: 10.1200/jco.2017.74.9705] [Cited by in Crossref: 81] [Cited by in F6Publishing: 43] [Article Influence: 16.2] [Reference Citation Analysis]
332 Sun R, Kong X, Qiu X, Huang C, Wong PP. The Emerging Roles of Pericytes in Modulating Tumor Microenvironment. Front Cell Dev Biol 2021;9:676342. [PMID: 34179005 DOI: 10.3389/fcell.2021.676342] [Reference Citation Analysis]
333 Nishida T, Doi T. A new approach to refractory gastrointestinal stromal tumours with diverse acquired mutations. Lancet Oncol 2020;21:864-5. [PMID: 32511982 DOI: 10.1016/S1470-2045(20)30209-6] [Reference Citation Analysis]
334 Ordog T, Zörnig M, Hayashi Y. Targeting Disease Persistence in Gastrointestinal Stromal Tumors. Stem Cells Transl Med 2015;4:702-7. [PMID: 25934947 DOI: 10.5966/sctm.2014-0298] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
335 Ehnman M, Larsson O. Microenvironmental Targets in Sarcoma. Front Oncol 2015;5:248. [PMID: 26583076 DOI: 10.3389/fonc.2015.00248] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
336 Yamaoka T, Kusumoto S, Ando K, Ohba M, Ohmori T. Receptor Tyrosine Kinase-Targeted Cancer Therapy. Int J Mol Sci 2018;19:E3491. [PMID: 30404198 DOI: 10.3390/ijms19113491] [Cited by in Crossref: 75] [Cited by in F6Publishing: 66] [Article Influence: 18.8] [Reference Citation Analysis]
337 Joensuu H, Blay JY, Comandone A, Martin-Broto J, Fumagalli E, Grignani G, Del Muro XG, Adenis A, Valverde C, Pousa AL, Bouché O, Italiano A, Bauer S, Barone C, Weiss C, Crippa S, Camozzi M, Castellana R, Le Cesne A. Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib. Br J Cancer 2017;117:1278-85. [PMID: 28850565 DOI: 10.1038/bjc.2017.290] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
338 Vincenzi B, Nannini M, Badalamenti G, Grignani G, Fumagalli E, Gasperoni S, D'Ambrosio L, Incorvaia L, Stellato M, Spalato Ceruso M, Napolitano A, Valeri S, Santini D, Tonini G, Casali PG, Dei Tos AP, Pantaleo MA. Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib. Ther Adv Med Oncol 2018;10:1758835918794623. [PMID: 30181783 DOI: 10.1177/1758835918794623] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
339 Mulet-Margalef N, Garcia-Del-Muro X. Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives. Onco Targets Ther. 2016;9:7573-7582. [PMID: 28008275 DOI: 10.2147/ott.s101385] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
340 Fairweather M, Balachandran VP, Li GZ, Bertagnolli MM, Antonescu C, Tap W, Singer S, DeMatteo RP, Raut CP. Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors: A 2-institutional Analysis. Ann Surg. 2018;268:296-302. [PMID: 28448384 DOI: 10.1097/sla.0000000000002281] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
341 De Wit M, Boers-Doets CB, Saettini A, Vermeersch K, de Juan CR, Ouwerkerk J, Raynard SS, Bazin A, Cremolini C. Prevention and management of adverse events related to regorafenib. Support Care Cancer 2014;22:837-46. [PMID: 24337717 DOI: 10.1007/s00520-013-2085-z] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 4.2] [Reference Citation Analysis]
342 Ruiz JN, Belum VR, Creel P, Cohn A, Ewer M, Lacouture ME. Current practices in the management of adverse events associated with targeted therapies for advanced renal cell carcinoma: a national survey of oncologists. Clin Genitourin Cancer 2014;12:341-7. [PMID: 25035283 DOI: 10.1016/j.clgc.2014.04.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
343 Yeh CN, Chang YC, Su Y, Shin-Shian Hsu D, Cheng CT, Wu RC, Chung YH, Chiang KC, Yeh TS, Lu ML, Liu CY, Mu-Hsin Chang P, Chen MH, Huang CF, Hsiao M, Chen MH. Identification of MALT1 as both a prognostic factor and a potential therapeutic target of regorafenib in cholangiocarcinoma patients. Oncotarget 2017;8:113444-59. [PMID: 29371921 DOI: 10.18632/oncotarget.23049] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
344 Guo T, Liu P, Yang J, Wu P, Chen B, Liu Z, Li Z. Evaluation of Targeted Agents for Advanced and Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis. J Cancer 2019;10:4671-8. [PMID: 31528232 DOI: 10.7150/jca.32828] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
345 Shah K, Chan KKW, Ko YJ. A systematic review and network meta-analysis of post-imatinib therapy in advanced gastrointestinal stromal tumour. Curr Oncol. 2017;24:e531-e539. [PMID: 29270063 DOI: 10.3747/co.24.3463] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
346 Ahmed M. Recent advances in the management of gastrointestinal stromal tumor. World J Clin Cases 2020; 8(15): 3142-3155 [PMID: 32874969 DOI: 10.12998/wjcc.v8.i15.3142] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
347 Sirohi B, Philip DS, Shrikhande SV. Regorafenib: carving a niche in the crowded therapeutic landscape. Expert Rev Anticancer Ther 2013;13:385-93. [PMID: 23560833 DOI: 10.1586/era.13.12] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
348 Fukuda S, Fujiwara Y, Wakasa T, Kitani K, Tsujie M, Yukawa M, Ohta Y, Inoue M. Giant gastric gastrointestinal stromal tumor with severe peritoneal dissemination controlled by imatinib therapy following debulking surgery: a case report. J Med Case Rep 2017;11:33. [PMID: 28166823 DOI: 10.1186/s13256-017-1215-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
349 Tsai TH, Chen YJ, Wang LY, Hsieh CH. Effect of Synchronous Versus Sequential Regimens on the Pharmacokinetics and Biodistribution of Regorafenib with Irradiation. Pharmaceutics 2021;13:386. [PMID: 33805831 DOI: 10.3390/pharmaceutics13030386] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
350 Roman D, Whiteside R. Regorafenib: Adding to the Armamentarium for Refractory Colorectal Cancer and GIST. J Adv Pract Oncol 2013;4:118-22. [PMID: 25031991 DOI: 10.6004/jadpro.2013.4.2.7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
351 Katayanagi S, Yokoyama T, Makuuchi Y, Osakabe H, Iwamoto H, Sumi T, Hirano H, Katsumata K, Tsuchida A, Hirota S, Kawachi S. Long-Term Survival After Multidisciplinary Treatment Including Surgery for Metachronous Metastases of Small Intestinal Gastrointestinal Stromal Tumors after Curative Resection: A Case Report. Am J Case Rep 2019;20:1942-8. [PMID: 31875847 DOI: 10.12659/AJCR.918606] [Reference Citation Analysis]
352 Boonstra PA, Ter Elst A, Tibbesma M, Bosman LJ, Mathijssen R, Atrafi F, van Coevorden F, Steeghs N, Farag S, Gelderblom H, van der Graaf WTA, Desar IME, Maier J, Overbosch J, Suurmeijer AJH, Gietema J, Schuuring E, Reyners AKL. A single digital droplet PCR assay to detect multiple KIT exon 11 mutations in tumor and plasma from patients with gastrointestinal stromal tumors. Oncotarget 2018;9:13870-83. [PMID: 29568401 DOI: 10.18632/oncotarget.24493] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
353 Reinwald M, Boch T, Hofmann WK, Buchheidt D. Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors. Biomark Insights 2015;10:55-68. [PMID: 27127405 DOI: 10.4137/BMI.S22430] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
354 Chen JS, Yeh CN, Cheng CT, Yen CC, Chen YY, Huang SC, Chiang KC, Yeh TS, Chen SC, Chao TC, Yang MH, Chao Y. Role of PLK1 signaling pathway genes in gastrointestinal stromal tumors. Oncol Lett 2018;16:3070-82. [PMID: 30127898 DOI: 10.3892/ol.2018.9003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
355 Ma MZ, Zhuang C, Yang XM, Zhang ZZ, Ma H, Zhang WM, You H, Qin W, Gu J, Yang S, Cao H, Zhang ZG. CTHRC1 acts as a prognostic factor and promotes invasiveness of gastrointestinal stromal tumors by activating Wnt/PCP-Rho signaling. Neoplasia 2014;16:265-78, 278.e1-13. [PMID: 24726140 DOI: 10.1016/j.neo.2014.03.001] [Cited by in Crossref: 46] [Cited by in F6Publishing: 53] [Article Influence: 5.8] [Reference Citation Analysis]
356 Ravegnini G, Sammarini G, Nannini M, Pantaleo MA, Biasco G, Hrelia P, Angelini S. Gastrointestinal stromal tumors (GIST): Facing cell death between autophagy and apoptosis. Autophagy 2017;13:452-63. [PMID: 28055310 DOI: 10.1080/15548627.2016.1256522] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
357 Gerisch M, Hafner FT, Lang D, Radtke M, Diefenbach K, Cleton A, Lettieri J. Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects. Cancer Chemother Pharmacol 2018;81:195-206. [PMID: 29188322 DOI: 10.1007/s00280-017-3480-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
358 Puccini A, Battaglin F, Lenz HJ. Management of Advanced Small Bowel Cancer. Curr Treat Options Oncol 2018;19:69. [PMID: 30397729 DOI: 10.1007/s11864-018-0592-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
359 Wang Z, Xu J, Nie W, Huang G, Tang J, Guan X. Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis. Eur J Clin Pharmacol 2014;70:225-31. [PMID: 24150533 DOI: 10.1007/s00228-013-1598-1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
360 Yoon H, Tang CM, Banerjee S, Delgado AL, Yebra M, Davis J, Sicklick JK. TGF-β1-mediated transition of resident fibroblasts to cancer-associated fibroblasts promotes cancer metastasis in gastrointestinal stromal tumor. Oncogenesis 2021;10:13. [PMID: 33568624 DOI: 10.1038/s41389-021-00302-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
361 Yang Q, Guo X, Yang L. Metformin Enhances the Effect of Regorafenib and Inhibits Recurrence and Metastasis of Hepatic Carcinoma After Liver Resection via Regulating Expression of Hypoxia Inducible Factors 2α (HIF-2α) and 30 kDa HIV Tat-Interacting Protein (TIP30). Med Sci Monit 2018;24:2225-34. [PMID: 29654226 DOI: 10.12659/msm.906687] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
362 Lassau N, Bonastre J, Kind M, Vilgrain V, Lacroix J, Cuinet M, Taieb S, Aziza R, Sarran A, Labbe-Devilliers C, Gallix B, Lucidarme O, Ptak Y, Rocher L, Caquot LM, Chagnon S, Marion D, Luciani A, Feutray S, Uzan-Augui J, Coiffier B, Benastou B, Koscielny S. Validation of dynamic contrast-enhanced ultrasound in predicting outcomes of antiangiogenic therapy for solid tumors: the French multicenter support for innovative and expensive techniques study. Invest Radiol. 2014;49:794-800. [PMID: 24991866 DOI: 10.1097/rli.0000000000000085] [Cited by in Crossref: 76] [Cited by in F6Publishing: 32] [Article Influence: 10.9] [Reference Citation Analysis]
363 Gillis NK, Rotroff DM, Mesa TE, Yao J, Chen Z, Carulli MA, Yoder SJ, Walko CM, Teer JK, McLeod HL. Tumor exome sequencing and copy number alterations reveal potential predictors of intrinsic resistance to multi-targeted tyrosine kinase inhibitors. Oncotarget 2017;8:115114-27. [PMID: 29383146 DOI: 10.18632/oncotarget.22914] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
364 McLellan B, Ciardiello F, Lacouture ME, Segaert S, Van Cutsem E. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. Ann Oncol. 2015;26:2017-2026. [PMID: 26034039 DOI: 10.1093/annonc/mdv244] [Cited by in Crossref: 61] [Cited by in F6Publishing: 46] [Article Influence: 8.7] [Reference Citation Analysis]
365 Chen J, Wang J, Lin H, Peng Y. Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials. Med Sci Monit 2019;25:9179-91. [PMID: 31790382 DOI: 10.12659/MSM.918411] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
366 Jia N, Tong H, Zhang Y, Katayama H, Wang Y, Lu W, Zhang S, Wang J. CeRNA Expression Profiling Identifies KIT-Related circRNA-miRNA-mRNA Networks in Gastrointestinal Stromal Tumour. Front Genet 2019;10:825. [PMID: 31552107 DOI: 10.3389/fgene.2019.00825] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
367 Yi JH, Park BB, Kang JH, Hwang IG, Shin DB, Sym SJ, Ahn HK, Lee SI, Lim DH, Park KW, Won YW, Lim SH, Park SH. Retrospective analysis of extra-gastrointestinal stromal tumors. World J Gastroenterol 2015; 21(6): 1845-1850 [PMID: 25684950 DOI: 10.3748/wjg.v21.i6.1845] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
368 Gheorghe G, Bacalbasa N, Ceobanu G, Ilie M, Enache V, Constantinescu G, Bungau S, Diaconu CC. Gastrointestinal Stromal Tumors-A Mini Review. J Pers Med 2021;11:694. [PMID: 34442339 DOI: 10.3390/jpm11080694] [Reference Citation Analysis]
369 Ravegnini G, Nannini M, Sammarini G, Astolfi A, Biasco G, Pantaleo MA, Hrelia P, Angelini S. Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA Analysis. Int J Mol Sci 2015;16:15592-608. [PMID: 26184165 DOI: 10.3390/ijms160715592] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
370 Heinrich MC, Patterson J, Beadling C, Wang Y, Debiec-Rychter M, Dewaele B, Corless CL, Duensing A, Raut CP, Rubin B, Ordog T, van de Rijn M, Call J, Mühlenberg T, Fletcher JA, Bauer S. Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs). Clin Sarcoma Res 2019;9:3. [PMID: 30867899 DOI: 10.1186/s13569-019-0112-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
371 Etherington MS, DeMatteo RP. Tailored management of primary gastrointestinal stromal tumors. Cancer. 2019;125:2164-2171. [PMID: 30933313 DOI: 10.1002/cncr.32067] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
372 Tsuchihashi K, Shimokawa H, Takayoshi K, Nio K, Aikawa T, Matsushita Y, Wada I, Arita S, Ariyama H, Kusaba H, Sonoda KH, Akashi K, Baba E. Regorafenib-induced retinal and gastrointestinal hemorrhage in a metastatic colorectal cancer patient with liver dysfunction: A case report. Medicine (Baltimore) 2017;96:e8285. [PMID: 29049226 DOI: 10.1097/MD.0000000000008285] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
373 Zhao B, Zhao H. Incidence and risk of regorafenib-induced hepatotoxicity. Oncotarget 2017;8:84102-11. [PMID: 29137408 DOI: 10.18632/oncotarget.21106] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
374 Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hermes B, Schütte J, Cameron S, Hohenberger P, Jost PJ, Al-Batran SE, Lindner LH, Bauer S, Wardelmann E, Nilsson B, Kallio R, Jaakkola P, Junnila J, Alvegård T, Reichardt P. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up. JAMA Oncol 2020;6:1241-6. [PMID: 32469385 DOI: 10.1001/jamaoncol.2020.2091] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 19.0] [Reference Citation Analysis]
375 Ben-Ami E, Barysauskas CM, von Mehren M, Heinrich MC, Corless CL, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Yap JT. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ann Oncol. 2016;27:1794-1799. [PMID: 27371698 DOI: 10.1093/annonc/mdw228] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 8.0] [Reference Citation Analysis]
376 Hsueh YS, Chang HH, Shan YS, Sun HS, Fletcher JA, Li CF, Chen LT. Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors. Oncogene 2019;38:6550-65. [PMID: 31363162 DOI: 10.1038/s41388-019-0900-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
377 Lim Y, Bang JI, Han SW, Paeng JC, Lee KH, Kim JH, Kang GH, Jeong SY, Park KJ, Kim TY. Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib. Eur J Nucl Med Mol Imaging 2017;44:757-64. [PMID: 27888325 DOI: 10.1007/s00259-016-3577-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
378 Joseph CP, Abaricia SN, Angelis MA, Polson K, Jones RL, Kang YK, Riedel RF, Schöffski P, Serrano C, Trent J, Tetzlaff ED, Si TD, Zhou T, Doyle A, Bauer S, Roche M, Havnaer T. Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors. Oncologist 2021;26:e622-31. [PMID: 33301227 DOI: 10.1002/onco.13632] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
379 Fleming K, McGuinness J, Kipgen D, Glen H, Spiliopoulou P. A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer. Case Rep Oncol Med 2018;2018:6927639. [PMID: 30402314 DOI: 10.1155/2018/6927639] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
380 Poveda A, Martinez V, Serrano C, Sevilla I, Lecumberri MJ, de Beveridge RD, Estival A, Vicente D, Rubió J, Martin-Broto J. SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016). Clin Transl Oncol 2016;18:1221-8. [PMID: 27896638 DOI: 10.1007/s12094-016-1579-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
381 Ronellenfitsch U, Henzler T, Menge F, Dimitrakopoulou-Strauss A, Hohenberger P. [Advanced gastrointestinal stromal tumors : What role does surgery currently play in multimodal concepts?]. Chirurg 2016;87:389-97. [PMID: 27080051 DOI: 10.1007/s00104-016-0180-7] [Reference Citation Analysis]
382 Haskal ZJ. Editor's suggested readings in interventional oncology. J Vasc Interv Radiol 2013;24:1165-6. [PMID: 23885914 DOI: 10.1016/j.jvir.2013.05.068] [Reference Citation Analysis]
383 Liu B, Ding F, Liu Y, Xiong G, Lin T, He D, Zhang Y, Zhang D, Wei G. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients. Oncotarget 2016;7:67661-73. [PMID: 27602778 DOI: 10.18632/oncotarget.11813] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
384 Cha Y, Kim HP, Lim Y, Han SW, Song SH, Kim TY. FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro. Mol Oncol 2018;12:993-1003. [PMID: 29573334 DOI: 10.1002/1878-0261.12194] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
385 Takaki H, Litchman T, Covey A, Cornelis F, Maybody M, Getrajdman GI, Sofocleous CT, Brown KT, Solomon SB, Alago W. Hepatic artery embolization for liver metastasis of gastrointestinal stromal tumor following imatinib and sunitinib therapy. J Gastrointest Cancer. 2014;45:494-499. [PMID: 25358551 DOI: 10.1007/s12029-014-9663-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
386 Wong SK, Chu QSC, Spratlin JL, Sangha R, McEwan AJB, Morrish DW, Arndt D, Sergenson G, Cleton A, Huang F, Sawyer MB. Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid Cancer. Case Rep Oncol 2019;12:791-5. [PMID: 31762750 DOI: 10.1159/000503419] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
387 Chhatrala R, Thanavala Y, Iyer R. Targeted therapy in gastrointestinal malignancies. J Carcinog 2014;13:4. [PMID: 24737952 DOI: 10.4103/1477-3163.127639] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
388 Sastre J, Argilés G, Benavides M, Feliú J, García-Alfonso P, García-Carbonero R, Grávalos C, Guillén-Ponce C, Martínez-Villacampa M, Pericay C. Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer. Clin Transl Oncol 2014;16:942-53. [PMID: 25223744 DOI: 10.1007/s12094-014-1212-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
389 Esteban-Villarrubia J, Soto-Castillo JJ, Pozas J, San Román-Gil M, Orejana-Martín I, Torres-Jiménez J, Carrato A, Alonso-Gordoa T, Molina-Cerrillo J. Tyrosine Kinase Receptors in Oncology. Int J Mol Sci 2020;21:E8529. [PMID: 33198314 DOI: 10.3390/ijms21228529] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
390 Martin-Broto J, Martinez-Marín V, Serrano C, Hindi N, López-Guerrero JA, Bisculoa M, Ramos-Asensio R, Vallejo-Benítez A, Marcilla-Plaza D, González-Cámpora R. Gastrointestinal stromal tumors (GISTs): SEAP-SEOM consensus on pathologic and molecular diagnosis. Clin Transl Oncol 2017;19:536-45. [PMID: 27943096 DOI: 10.1007/s12094-016-1581-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
391 Roulleaux Dugage M, Jones RL, Trent J, Champiat S, Dumont S. Beyond the Driver Mutation: Immunotherapies in Gastrointestinal Stromal Tumors. Front Immunol 2021;12:715727. [PMID: 34489967 DOI: 10.3389/fimmu.2021.715727] [Reference Citation Analysis]
392 Zhu JQ, Ou WB. Therapeutic targets in gastrointestinal stromal tumors. World J Transl Med 2015; 4(1): 25-37 [DOI: 10.5528/wjtm.v4.i1.25] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
393 Yoon H, Tang CM, Banerjee S, Yebra M, Noh S, Burgoyne AM, Torre J, Siena M, Liu M, Klug LR, Choi YY, Hosseini M, Delgado AL, Wang Z, French RP, Lowy A, DeMatteo RP, Heinrich MC, Molinolo AA, Gutkind JS, Harismendy O, Sicklick JK. Cancer-associated fibroblast secretion of PDGFC promotes gastrointestinal stromal tumor growth and metastasis. Oncogene 2021;40:1957-73. [PMID: 33603171 DOI: 10.1038/s41388-021-01685-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
394 Akahoshi K, Oya M, Koga T, Shiratsuchi Y. Current clinical management of gastrointestinal stromal tumor. World J Gastroenterol 2018; 24(26): 2806-2817 [PMID: 30018476 DOI: 10.3748/wjg.v24.i26.2806] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 55] [Article Influence: 18.0] [Reference Citation Analysis]
395 Xu K, Zhang Q, Chen M, Li B, Wang N, Li C, Gao Z, Zhang D, Yang L, Xu Z, Li X, Xu H. N6-methyladenosine modification regulates imatinib resistance of gastrointestinal stromal tumor by enhancing the expression of multidrug transporter MRP1. Cancer Lett 2022:S0304-3835(22)00016-7. [PMID: 35032557 DOI: 10.1016/j.canlet.2022.01.008] [Reference Citation Analysis]
396 Choe J, Riedel R. Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas. F1000Res 2018;7:F1000 Faculty Rev-1737. [PMID: 30450193 DOI: 10.12688/f1000research.15868.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
397 Rutkowski P, Jagielska B, Andrzejuk J, Bylina E, Lugowska I, Switaj T, Kosela-Paterczyk H, Kozak K, Falkowski S, Klimczak A. The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST). Contemp Oncol (Pozn) 2017;21:285-9. [PMID: 29416434 DOI: 10.5114/wo.2017.72393] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
398 Poveda A, del Muro XG, López-Guerrero JA, Martínez V, Romero I, Valverde C, Cubedo R, Martín-Broto J. GEIS 2013 guidelines for gastrointestinal sarcomas (GIST). Cancer Chemother Pharmacol. 2014;74:883-898. [PMID: 25193432 DOI: 10.1007/s00280-014-2547-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
399 Kongsuphon N, Soukavanitch M, Teeraaumpornpunt N, Konmun J, Ativitavas T, Ngamphaiboon N. Multi-Targeted Tyrosine Kinase Inhibitor-Induced Hyperammonemic Encephalopathy: a Report of Two Cases Using Pazopanib, Sunitinib, and Regorafenib. J Gastrointest Cancer 2019;50:601-3. [PMID: 29411249 DOI: 10.1007/s12029-018-0067-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
400 Nishida T. Asian consensus guidelines for gastrointestinal stromal tumor: what is the same and what is different from global guidelines. Transl Gastroenterol Hepatol 2018;3:11. [PMID: 29552662 DOI: 10.21037/tgh.2018.01.07] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
401 Liu S, Pan P, Han B, Wang J, Sun M, Sun Y. Extragastrointestinal Stromal Tumor Presenting as a Recurrent Vaginal Mass: Case Report. Onco Targets Ther 2021;14:959-65. [PMID: 33603400 DOI: 10.2147/OTT.S284101] [Reference Citation Analysis]
402 Subbiah V. Prospects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderly. Curr Oncol Rep 2014;16:401. [PMID: 25030655 DOI: 10.1007/s11912-014-0401-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
403 Duffaud F, Le Cesne A. Recent advances in managing gastrointestinal stromal tumor. F1000Res. 2017;6:1689. [PMID: 28928967 DOI: 10.12688/f1000research.11118.1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
404 Hu CH, Yeh CN, Chen JS, Tsai CY, Wang SY, Cheng CT, Yeh TS. Regorafenib treatment outcome for Taiwanese patients with metastatic gastrointestinal stromal tumors after failure of imatinib and sunitinib: A prospective, non-randomized, single-center study. Oncol Lett 2020;20:2131-42. [PMID: 32782530 DOI: 10.3892/ol.2020.11756] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
405 Belum VR, Cercek A, Sanz-Motilva V, Lacouture ME. Dermatologic adverse events to targeted therapies in lower GI cancers: clinical presentation and management. Curr Treat Options Oncol 2013;14:389-404. [PMID: 23996476 DOI: 10.1007/s11864-013-0254-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
406 Kang YK, Yoo C, Ryoo BY, Lee JJ, Tan E, Park I, Park JH, Choi YJ, Jo J, Ryu JS, Ryu MH. Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib. Br J Cancer 2013;109:2309-15. [PMID: 24084771 DOI: 10.1038/bjc.2013.594] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 4.4] [Reference Citation Analysis]
407 Wei F, Wang M, Li Z, Wang Y, Zhou Y. Long Non-coding RNA MIR570MG Causes Regorafenib Resistance in Colon Cancer by Repressing miR-145/SMAD3 Signaling. Front Oncol 2020;10:291. [PMID: 32195190 DOI: 10.3389/fonc.2020.00291] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
408 Chamberlain F, Farag S, Williams-Sharkey C, Collingwood C, Chen L, Mansukhani S, Engelmann B, Al-Muderis O, Chauhan D, Thway K, Fisher C, Jones RL, Gennatas S, Benson C. Toxicity management of regorafenib in patients with gastro-intestinal stromal tumour (GIST) in a tertiary cancer centre. Clin Sarcoma Res 2020;10:1. [PMID: 31911828 DOI: 10.1186/s13569-019-0123-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
409 Bauer S, George S, von Mehren M, Heinrich MC. Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor. Front Oncol 2021;11:672500. [PMID: 34322383 DOI: 10.3389/fonc.2021.672500] [Reference Citation Analysis]
410 D'Angelo SP, Shoushtari AN, Keohan ML, Dickson MA, Gounder MM, Chi P, Loo JK, Gaffney L, Schneider L, Patel Z, Erinjeri JP, Bluth MJ, Sjoberg A, Streicher H, Takebe N, Qin LX, Antonescu C, DeMatteo RP, Carvajal RD, Tap WD. Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. Clin Cancer Res 2017;23:2972-80. [PMID: 28007774 DOI: 10.1158/1078-0432.CCR-16-2349] [Cited by in Crossref: 60] [Cited by in F6Publishing: 37] [Article Influence: 10.0] [Reference Citation Analysis]
411 Li J, Ye Y, Wang J, Zhang B, Qin S, Shi Y, He Y, Liang X, Liu X, Zhou Y, Wu X, Zhang X, Wang M, Gao Z, Lin T, Cao H, Shen L, Chinese Society Of Clinical Oncology Csco Expert Committee On Gastrointestinal Stromal Tumor. Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor. Chin J Cancer Res 2017;29:281-93. [PMID: 28947860 DOI: 10.21147/j.issn.1000-9604.2017.04.01] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 9.4] [Reference Citation Analysis]
412 Lanke G, Lee JH. How best to manage gastrointestinal stromal tumor. World J Clin Oncol 2017; 8(2): 135-144 [PMID: 28439494 DOI: 10.5306/wjco.v8.i2.135] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
413 Serrano C, Mariño-Enríquez A, Tao DL, Ketzer J, Eilers G, Zhu M, Yu C, Mannan AM, Rubin BP, Demetri GD, Raut CP, Presnell A, McKinley A, Heinrich MC, Czaplinski JT, Sicinska E, Bauer S, George S, Fletcher JA. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. Br J Cancer 2019;120:612-20. [PMID: 30792533 DOI: 10.1038/s41416-019-0389-6] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 16.0] [Reference Citation Analysis]
414 He J, Ahuja N. Personalized Approaches to Gastrointestinal Cancers: Importance of Integrating Genomic Information to Guide Therapy. Surg Clin North Am 2015;95:1081-94. [PMID: 26315525 DOI: 10.1016/j.suc.2015.05.002] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
415 Matuszewska K, Pereira M, Petrik D, Lawler J, Petrik J. Normalizing Tumor Vasculature to Reduce Hypoxia, Enhance Perfusion, and Optimize Therapy Uptake. Cancers (Basel) 2021;13:4444. [PMID: 34503254 DOI: 10.3390/cancers13174444] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
416 Lebron MB, Brennan L, Damoci CB, Prewett MC, O'Mahony M, Duignan IJ, Credille KM, DeLigio JT, Starodubtseva M, Amatulli M, Zhang Y, Schwartz KD, Burtrum D, Balderes P, Persaud K, Surguladze D, Loizos N, Paz K, Kotanides H. A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth. Cancer Biol Ther 2014;15:1208-18. [PMID: 24921944 DOI: 10.4161/cbt.29523] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
417 Pimenta JR, Racy DJ, Zapata LM, D'Alpino Peixoto R. Durable Disease Control with Regorafenib in a Patient with Metastatic KIT-Mutated Colorectal Cancer. J Gastrointest Cancer 2021;52:784-7. [PMID: 32944848 DOI: 10.1007/s12029-020-00523-8] [Reference Citation Analysis]
418 Mei L, Du W, Idowu M, von Mehren M, Boikos SA. Advances and Challenges on Management of Gastrointestinal Stromal Tumors. Front Oncol. 2018;8:135. [PMID: 29868467 DOI: 10.3389/fonc.2018.00135] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]